Randomized data are lacking on the optimal duration of dual-antiplatelet therapy after drug-eluting stent implantation and on the risks associated with discontinuation of dual-antiplatelet therapy. Despite the absence of randomized data, the use of dual-antiplatelet therapy beyond 1 year has become commonplace in clinical practice. In the j-Cypher registry, 10,778 Japanese patients treated exclusively by sirolimus-eluting stents were followed up for up to 2 years with prospective data collection on the status of antiplatelet therapy during follow-up. Incidences of definite stent thrombosis were 0.34% at 30 days, 0.54% at 1 year, and 0.77% at 2 years. Thienopyridine use was maintained in 97%, 62%, and 50% of patients at 30 days, 1 year, and 2 years, respectively. The main findings of the present study were that discontinuation of both aspirin and thienopyridine, but not discontinuation of thienopyridine therapy only, was associated with an increased stent thrombosis risk and that no apparent clinical benefit of thienopyridine use could be seen beyond 6 months after sirolimus-eluting stent implantation, according to the 6-month landmark analysis. Given the increased risk of bleeding and huge economic burden associated with prolonged dual-antiplatelet therapy, the optimal duration of dual-antiplatelet therapy should be defined by prospective randomized trials evaluating its net clinical benefit after consideration of both ischemic events and bleeding complications Conclusions: Discontinuation of both thienopyridine and aspirin, but not discontinuation of thienopyridine therapy only, was associated with an increased risk of stent thrombosis. Landmark analysis did not suggest an apparent clinical benefit of thienopyridine use beyond 6 months after sirolimus-eluting stent implantation. 1 Summary: Drug-eluting stent implantation in acute myocardial infarction is associated with an increased risk for acute and subacute in-stent thrombosis. Increased platelet activity also has been ob-Correspondence to: The Editors, Circulation Editorial Office, Summary: Contemporary consensus treatment guidelines continue to recommend coronary artery bypass grafting (CABG) as the "gold standard" for revascularization of unprotected left main (LM) stenosis but note that percutaneous coronary intervention (PCI) is feasible; for example, the American College of Cardiology/American Heart Association PCI guidelines recently upgraded LM PCI from a class III to class IIb (level B) recommendation. In the absence of a large randomized controlled trial, interventional cardiologists have had difficulty developing objective evidence-based criteria for determining the optimal revascularization strategy for a given patient. The Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial is the first large trial to randomize patients suitable for revascularization by either CABG or PCI using drug-eluting stents for the treatment of LM and/or 3-vessel disease. This article presents outcomes in the prespecified subgroup of patients (Nϭ705) with LM disease. Patients with LM disease had comparable overall 12-month major adverse cardiovascular and cerebrovascular events in both the PCI and the CABG group (14% CABG versus 16% PCI). When patients were scored for anatomic complexity, those with higher baseline SYNTAX scores had significantly worse outcomes with PCI than those with low or intermediate SYNTAX scores; outcomes for patients with CABG did not correlate with baseline SYNTAX score. Thus, this short-term (1-year) analysis suggests that patients with LM disease who have low or intermediate SYNTAX scores may be safely treated with either PCI or CABG, but longer follow-up is needed.
Safety of Short-Term Discontinuation of Antiplatelet Therapy in Patients With Drug-Eluting Stents
Summary: We identified 161 cases of late stent thrombosis or very late stent thrombosis from 84 articles in a systematic Medline search. Patients had a mean age of 58.4Ϯ13.4 years, and 88% were male. A total of 19 cases occurred in patients who were receiving dual antiplatelet therapy at the time of the event. If patients stopped both a thienopyridine and acetylsalicylic acid simultaneously, the median time to event was 7 days. If patients had previously stopped a thienopyridine with no ill effect and subsequently stopped acetylsalicylic acid, the median time to event was also 7 days. If a thienopyridine was stopped but acetylsalicylic acid was maintained, the median time to event was 122 days. Among the 48 patients who stopped both agents, 36 cases (75%) occurred within 10 days. Among the 94 patients who stopped a thienopyridine but not acetylsalicylic acid, only 6 cases (6%) occurred within 10 days. If acetylsalicylic acid therapy is maintained, short-term discontinuation of a thienopyridine may be relatively safe in patients with drugeluting stents.
Conclusions: If acetylsalicylic acid therapy is maintained, short-term discontinuation of a thienopyridine may be relatively safe in patients with drug-eluting stents. 2
Paclitaxel-Coated Balloon Catheter versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis
Summary: Drug-eluting stents are currently considered the best possible care in the treatment of in-stent restenosis. However, they include the presence of 2 layers of metal and may further reduce the flexibility of the vessel and limit the repeatability of the procedure. First-in-human trials with short-time local drug delivery using a paclitaxel-coated balloon catheter as compared with plain balloon angioplasty have shown beneficial effects in the treatment of coronary in-stent restenosis and in peripheral arteries. The PEPCAD (Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease) II trial compares the drug-coated SeQuent Please balloon with the approved and recognized drug-eluting Taxus Liberté stent. Angiographic late lumen loss was significantly lower with the coated balloon as compared with the drug-eluting stent. Furthermore, there was a trend toward a reduction of clinical events. Treatment of coronary in-stent restenosis with the paclitaxel-coated balloon was at least as efficacious and as well tolerated as the paclitaxel-eluting stent. For the treatment of in-stent restenosis, inhibition of rerestenosis does not require a second stent implantation.
Conclusions: Treatment of coronary in-stent restenosis with the paclitaxel-coated balloon was at least as efficacious and as well tolerated as the paclitaxel-eluting stent. For the treatment of in-stent restenosis, inhibition of rerestenosis does not require a second stent implantation. 3 served in acute myocardial infarction. Therefore, more aggressive antiplatelet therapy rather than conventional dual antiplatelet therapy may offer extra benefits for acute myocardial infarction patients undergoing primary percutaneous coronary intervention with drugeluting stents. This article retrospectively evaluates the safety and efficacy of triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol; nϭ1634) and dual antiplatelet therapy (aspirin plus clopidogrel; nϭ2569) in 4203 ST-segment elevation myocardial infarction patients who underwent primary percutaneous coronary intervention with drug-eluting stents. Selection of patients for treatment with triple antiplatelet therapy was left to the physician's discretion. Compared with dual antiplatelet therapy, triple antiplatelet therapy had a similar incidence of major bleeding events but a significantly lower incidence of in-hospital mortality. After adjustment for known confounders, triple antiplatelet therapy had significantly lower incidences of cardiac death (adjusted odds ratio, 0.52; 95% confidence interval, 0.32-0.84; Pϭ0.007), total death (adjusted odds ratio, 0.60; 95% confidence interval, 0.41-0.89; Pϭ0.010), and total major adverse cardiac events (adjusted odds ratio, 0.74; 95% confidence interval, 0.58 -0.95; Pϭ0.019) at 8 months than dual antiplatelet therapy. In this large, real-world clinical study in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention with drug-eluting stents, triple antiplatelet therapy not only had a good safety profile but also improved midterm clinical outcomes. Randomized trials are needed to compare the safety and efficacy of the triple and dual antiplatelet therapies in these patients Conclusions: Triple antiplatelet therapy seems to be superior to dual antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stents. These results may provide the rationale for the use of triple antiplatelet therapy in these patients. 4 
Primary Angioplasty versus Fibrinolysis in Acute Myocardial Infarction: Long-Term Follow-Up in the Danish Acute Myocardial Infarction 2 Trial
Summary: The Danish Acute Myocardial Infarction 2 (DANAMI-2) study was a randomized multicenter investigation comparing fibrinolytic treatment and primary percutaneous coronary intervention (pPCI) in patients with ST-segment elevation myocardial infarction. It consisted of 2 substudies: a substudy of patients randomized at noninvasive referral hospitals where the pPCI arm included transfer for pPCI and a substudy of patients randomized at hospitals with interventional facilities. The study was terminated prematurely when the third interim analysis showed a significant benefit of pPCI in the referral hospital substudy. The present study investigated the longterm outcome. The primary end point consisted of death and reinfarction with a median follow-up of 7.8-years. In the overall cohort, pPCI reduced the composite end point from 41.3% in the fibrinolysis arm to 34.8% (Pϭ0.003), reduced reinfarction by an absolute 6.8% (PϽ0.001), and reduced death by an absolute 3.5% (Pϭ0.14). In the referral hospital substudy, pPCI reduced reinfarction by 5.5% (Pϭ0.006) and mortality by 6.6% (Pϭ0.03). In the smaller invasive hospital substudy, which was terminated after inclusion of only half of the planned number of patients, reinfarction was reduced by 10.2% (Pϭ0.002). The results indicate that transfer from noninvasive referral hospitals to invasive hospitals is associated with a significant improvement in long-term clinical outcome.
Conclusions: The benefit of pPCI over fibrinolysis was maintained at a long-term follow-up. pPCI reduced the risk of reinfarction in the overall cohort and reduced reinfarction and mortality among patients randomized at referral hospitals. This result reinforces that pPCI should be offered to ST-segment elevation myocardial infarction patients when interhospital transport to an invasive hospital can be completed within 120 minutes. 5
Randomized Study of the Crush Technique versus Provisional Side-Branch Stenting in True Coronary Bifurcations: The CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study
Summary: The optimal strategy in the percutaneous treatment of true coronary bifurcation lesions has not been fully clarified. In this 350-patient randomized multicenter trial, we compared the "crush" technique of electively stenting both branches versus stenting only the main branch, with provisional side-branch stenting if needed, with sirolimus-eluting stents. Regardless of the technique used, sirolimus-eluting stent implantation in true bifurcation lesions results in good clinical and angiographic results with acceptable midterm safety. The rates of angiographic restenosis, stent thrombosis, and major adverse cardiovascular events at 6 months were similar in both groups. Thus, in most bifurcations with a significant stenosis in both branches, a provisional strategy of stenting the main branch only is effective, with the need to implant a second stent on the side branch occurring in approximately one third of cases. However, if 2 stents are required and are implanted with the crush technique, there appears to be no increased risk of adverse events at 6 months.
Conclusions:
In most bifurcations with a significant stenosis in both branches, a provisional strategy of stenting the main branch only is effective, with the need to implant a second stent on the side branch occurring in approximately one third of cases. The implantation of 2 stents does not appear to be associated with a higher incidence of adverse events at 6 months. 6 Summary: Bleeding is the most common noncardiac complication after percutaneous coronary intervention, associated with increased morbidity, mortality, length of hospitalization, and cost. In this work, we identified clinical risk factors associated with postpercutaneous coronary intervention bleeding in Ͼ300 000 patients from the National Cardiovascular Data Registry. From a best-fitting model of 15 risk factors, we developed a simplified clinical model consisting of the 9 most significant and clinically useful variables. Using the simplified model, a risk scoring algorithm is presented with points assigned based on the presence of these variables. A patient's risk score is calculated using the sum of the points; larger scores correspond with increased risk. Three risk categories are presented: low (Յ7 points), medium (8 -17 points) , and high (Ն18 points). This clinical risk model is actionable because there are known strategies to reduce postpercutaneous coronary intervention bleeding. Incorporation of this risk algorithm into everyday cardiology practice is feasible and may reduce resource utilization and mitigate bleeding risk in patients undergoing percutaneous coronary intervention.
Conclusions: This report identifies baseline clinical factors associated with bleeding and proposes a clinically useful algorithm to estimate bleeding risk. This model is potentially actionable in altering therapeutic decision making and improving outcomes in patients undergoing PCI. 9
Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: A Prospective, Randomized Control Trial
Summary: A transient sublethal episode of ischemia before a prolonged ischemia/reperfusion injury (ischemic preconditioning) offers a powerful endogenous protective strategy to reduce infarct size. Although readily demonstrable in animal models, the translation from bench to bedside has been slow. Clinical application of ischemic preconditioning is limited by restricted access to tissues requiring protection, safety issues, and the temporality of the therapeutic effect. However, protection can spread to distant tissues through remote ischemic preconditioning. Preemptive remote ischemic preconditioning of ischemia-resistant skeletal tissue to protect distant myocardium before potential coronary stent-induced infarction (4a myocardial infarction) circumvents some of the limitations that potentially impede the demonstration of clinical benefit. The novel results of the present randomized control study in 242 patients undergoing elective percutaneous coronary intervention (PCI) demonstrate that remote IPC (induced by three 5-minute inflations of a blood pressure cuff to 200 mm Hg around the upper arm, followed by 5-minute intervals of reperfusion, Ϸ1 hour before PCI) reduced median troponin I release at 24 hours after the procedure (0.06 versus 0.16 ng/mL; Pϭ0.04), chest pain, and ST deviation during the procedure (PϽ0.005) and major adverse cardiac and cerebral event rate at 6 months (4 versus 13 events; Pϭ0.04). Protection was time dependent, with the greatest benefit observed in those with shorter cuff-to-balloon times. The implication of this real-world study is that remote ischemic preconditioning has therapeutic benefit to reduce ischemic chest discomfort and subsequent myocardial infarction after elective PCI and that this simple, safe, and cheap procedure has the potential to affect the prognosis of patients with stable coronary disease treated with coronary stent implantation.
Conclusions: Remote IPC reduces ischemic chest discomfort during PCI, attenuates procedure-related cTnI release, and appears to reduce subsequent cardiovascular events. 10 
Economic Evaluation of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients With Multivessel Disease
Summary: The Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) study demonstrated that performing percutaneous coronary intervention guided by fractional flow reserve measurement in patients with multivessel coronary artery disease leads to improved outcomes at 1 year compared with the traditional approach of using angiography alone to guide percutaneous coronary intervention. In this economic evaluation of the FAME study, we find that a fractional flow reserve-guided strategy not only improves outcomes but also saves money at 1 year. This finding provides further support for the routine measurement of fractional flow reserve in patients with multivessel coronary artery disease undergoing percutaneous coronary intervention.
Conclusions: Economic evaluation of the FAME study reveals that FFR-guided percutaneous coronary intervention in patients with multivessel coronary disease is one of those rare situations in which a new technology not only improves outcomes but also saves resources. 11
Abciximab in Patients With Acute ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading: A Randomized Double-Blind Trial
Summary: Several previous randomized trials have shown that the glycoprotein IIb/IIIa receptor inhibitor abciximab can improve outcomes after primary percutaneous coronary interventions in patients with acute ST-segment-elevation myocardial infarction. A high loading dose of clopidogrel is increasingly being used before primary percutaneous coronary intervention. The role of abciximab has not been investigated in patients undergoing primary percutaneous coronary intervention if given after clopidogrel loading. The aim of the Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) trial was to assess whether upstream administration of abciximab reduces infarct size in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after treatment with 600 mg clopidogrel. Left ventricular infarct size was measured by single-photon emission computed tomography with technetium-99m sestamibi performed before discharge. Of the 800 patients enrolled in this multicenter, double-blind, placebo controlled randomized trial, 401 patients were assigned to receive abciximab plus a reduced dose of heparin and 399 patients to receive placebo plus a full dose of heparin. Full restoration of flow in the infarct-related artery was achieved in comparable proportions of patients in both groups. Administration of abciximab was not associated with a reduction in infarct size. In addition, this drug did not reduce the combined incidence of all-cause death, recurrent myocardial infarction, stroke, and urgent revascularization of the infarct-related artery over 30 days after randomization. Therefore, abciximab administration might not be needed in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after loading with 600 mg clopidogrel.
Conclusions: Upstream administration of abciximab is not associated with a reduction in infarct size in patients presenting with acute myocardial infarction within 24 hours of symptom onset and receiving 600 mg clopidogrel. 12 
Intracoronary versus Intravenous Administration of Abciximab in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention With Thrombus Aspiration: The Comparison of Intracoronary versus Intravenous Abciximab Administration During Emergency Reperfusion of ST-Segment Elevation Myocardial Infarction (CICERO) Trial
Summary: Administration of the glycoprotein IIb/IIIa inhibitor abciximab is an effective adjunctive antiplatelet strategy during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Experimental studies have reported that higher local concentrations of abciximab exert additional effects, including disaggregation of newly formed thrombus, and can be achieved by intracoronary administration. Recently, small-scale studies have suggested beneficial clinical effects of intracoronary over intravenous administration. In the present Comparison of Intracoronary versus Intravenous Abciximab Administration During Emergency Reperfusion of ST-Segment Elevation Myocardial Infarction (CICERO) trial, 534 ST-segment elevation myocardial infarction patients were randomized within 12 hours of symptom onset to either an intracoronary or an intravenous bolus of abciximab during primary percutaneous coronary intervention with thrombus aspiration. Patients were pretreated with aspirin, heparin, and highdose clopidogrel. Intracoronary administration of abciximab compared with intravenous administration did not improve the rate of successful myocardial reperfusion as assessed by ST-segment resolution. In contrast, intracoronary administration was associated with a significantly higher rate of successful myocardial reperfusion as assessed by myocardial blush grade and a smaller enzymatic infarct size. In addition, bleeding complications occurred at similar frequencies between both treatment groups. Although intracoronary administration did not improve the primary end point of ST-segment resolution, the beneficial effects on secondary end points may translate into improved clinical outcome. Larger randomized multicenter trials are required to investigate whether intracoronary administration of abciximab reduces major adverse cardiac events.
Conclusions:
In ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with thrombus aspiration, intracoronary administration of abciximab compared with intravenous administration does not improve myocardial reperfusion as assessed by ST-segment resolution. However, intracoronary administration is associated with improved myocardial reperfusion as assessed by myocardial blush grade and a smaller enzymatic infarct size. 13 
Correlation of Intravascular Ultrasound Findings With Histopathologic Analysis of Thrombus Aspirates in Patients With Very Late Drug-Eluting Stent Thrombosis
Summary: Very late stent thrombosis (ST) is a distinct entity complicating the use of first-generation drug-eluting stents, resulting in abrupt coronary artery closure, myocardial infarction, or sudden death. Autopsy studies of patients with very late ST showed extensive vasculitis of the intima, media, and adventitia as well as hypersensitivity reactions. With the use of intravascular ultrasound in patients presenting with very late ST, an exceedingly high prevalence of incomplete stent apposition has been reported in concert with positive arterial remodeling. The present report correlates intravascular ultrasound findings with the results of histopathologic analysis of thrombi harvested from the occluded coronary artery at the time of very late ST. We observed signs of acute and chronic inflammation. Eosinophilic infiltrates were more common in patients with very late ST compared with control specimens. In addition, the number of eosinophils correlated with the extent of stent malapposition.
Conclusions: Very late DES thrombosis is associated with histopathologic signs of inflammation and intravascular ultrasound evidence of vessel remodeling. Compared with other causes of myocardial infarction, eosinophilic infiltrates are more common in thrombi harvested from very late DES thrombosis, particularly in sirolimus-eluting stents, and correlate with the extent of stent malapposition. 14
Retrograde Percutaneous Recanalization of Chronic Total Occlusion of the Coronary Arteries: Procedural Outcomes and Predictors of Success in Contemporary Practice
Summary: Procedural success rate for chronic total occlusion of the coronary arteries has been improving over time but is still suboptimal and is mainly due to failure to cross the lesion in the antegrade fashion. Recently, retrograde wire-crossing techniques have been introduced to improve recanalization rates. Therefore, we examined the procedural details of retrograde approaches through collateral channels for the treatment of chronic total occlusion among 157 consecutive patients at a single hospital in Japan from 2003 to 2008.
A total of 118 (75.2%) of these patients had a previously failed antegrade approach. Septal, epicardial, and saphenous vein graft collaterals were used in 67.5%, 24.8%, and 7.6% of cases, respectively. The collateral channel was crossed by guide wire successfully in 115 (73.2%) cases, and the procedure was successful by retrograde approach in 103 (65.6%) cases. The success rate with retrograde approach was higher in patients who had the retrograde as the first attempt when compared with patients with previously failed antegrade approaches (83% versus 61.5%; Pϭ0.01). The baseline demographics and angiographic features were similar between the success and failure groups. Inability to cross the collateral channel was the predominant reason for failure. We have identified epicardial channel use (Pϭ0.01), corkscrew tortuosity of the channel (Pϭ0.011), and angle of vessel with collateral Ͼ90°(Pϭ0.024) as significant predictors of failure. The major adverse cardiac events rate was acceptable (4.5%), and septal collateral perforation was seen in 3.8% of patients. The retrograde procedures for chronic total occlusion percutaneous coronary intervention are safe and effective in experienced hands, and further refinement of the technique is needed to improve the overall results.
Conclusions:
The retrograde approach in chronic total occlusion percutaneous coronary intervention is effective in recanalizing chronic total occlusion. The success rate by retrograde approach was 65.6%, and final success was 85% in this group with acceptable overall adverse events. We have identified predictors of failure related to collateral morphology. 15
Comparison of Primary Percutaneous Coronary Intervention and Fibrinolytic Therapy in ST-Segment-Elevation Myocardial Infarction: Bayesian Hierarchical Meta-Analyses of Randomized Controlled Trials and Observational Studies
Summary: The American Heart Association Mission Lifeline recently recommended major reorganizations in the structures and processes involved in reperfusion therapy for acute myocardial infarction with ST-segment elevation. In view of the major investments required for these reorganizations, systematic reviews of randomized controlled trials (RCTs) and observational studies to compare primary percutaneous coronary intervention and fibrinolytic therapy in diverse patient populations and clinical contexts are particularly timely. Meta-analyses of both RCTs and observational studies are consistent in showing short-term reductions in mortality and reinfarction with primary percutaneous coronary intervention, attesting to the superiority of this reperfusion strategy. The smaller reductions in short-term mortality and reinfarction with primary percutaneous coronary intervention reported in observational studies compared with RCTs may relate to confounding and selection bias, as well as less optimal application of primary percutaneous coronary intervention in the real world. The inconclusive evidence in observational studies for differences between the 2 reperfusion strategies in long-term mortality and reinfarction may be due to optimal long-term medical therapy and coronary intervention in the patients who received fibrinolytic therapy that may have attenuated the early benefits associated with primary percutaneous coronary intervention. The potential benefits of prehospital fibrinolysis could not be ascertained in this systematic review and may be better evaluated in large RCTs and observational studies.
Conclusions: Compared with fibrinolytic therapy, primary percutaneous coronary intervention was associated with short-term reductions in mortality, reinfarction, and stroke in ST-segment-elevation myocardial infarction. Primary percutaneous coronary intervention was associated with long-term reductions in mortality and reinfarction in RCTs, but there was no conclusive evidence for a long-term benefit in mortality and reinfarction in observational studies. 16 
Comparisons of Baseline Demographics, Clinical Presentation, and Long-Term Outcome Among Patients With Early, Late, and Very Late Stent Thrombosis of Sirolimus-Eluting Stents: Observations From the Registry of Stent Thrombosis for Review and Reevaluation (RESTART)
Summary: Stent thrombosis (ST) after sirolimus-eluting stent implantation has not yet been adequately characterized, mainly because of its low incidence. Pϭ0.009). From these findings, distinguishing between LST and VLST in future investigations of ST seems to be crucial. ST timingdependent differences in baseline demographic features, Thrombolysis in Myocardial Infarction flow grade, and mortality rate suggest possible differences in the predominant pathophysiological mechanisms of ST according to timing after sirolimus-eluting stent implantation.
Conclusions: ST timing-dependent differences in baseline demographic features, Thrombolysis in Myocardial Infarction flow grade, and mortality rate suggest possible differences in the predominant pathophysiological mechanisms of ST according to timing after sirolimus-eluting stent implantation. 17
Usefulness of the SYNTAX Score for Predicting Clinical Outcome After Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery Disease
Summary: The SYNTAX score has been recently proposed as an aid in decision making for patients with complex coronary artery disease, such as 3-vessel or left main coronary artery disease. This study validates and supports the prognostic value of this angiographic tool in patient with left main coronary artery disease. We found that the SYNTAX score is able to stratify patients according to their 1-year risk of cardiac death or major adverse cardiac events after percutaneous coronary intervention, even after adjustment for potential confounders. On the basis of this analysis, we suggested a cutoff of 34 to identify patients who may potentially benefit from surgery because of their poor outcome estimated with percutaneous coronary intervention.
Conclusions:
The SXscore is a useful tool to predict cardiac mortality and MACE in patients undergoing percutaneous revascularization of the left main coronary artery. 18
Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Study
Summary: Previous studies have shown that individual response to aspirin or clopidogrel intake may vary significantly among patients, and those who respond less have been reported to be at higher risk for worse cardiovascular outcomes, especially if treated with percutaneous coronary intervention. It is unknown whether this worse cardiovascular outcome directly reflects suboptimal platelet inhibition per se, which might benefit from more potent antiplatelet agents. Alternatively, this may simply represent a "marker" of worse prognosis without clear therapeutic implications. In this study, we have shown that intensifying platelet inhibition through the use of tirofiban, a potent intravenous antiplatelet agent, in patients undergoing percutaneous coronary intervention who have previously been selected to be poor responders to aspirin, clopidogrel, or both agents leads to lower incidence of periprocedural myocardial infarction compared with standard care consisting of aspirin and clopidogrel. Thus, data are provided for the first time showing that implementing alterative treatment strategies in this patient population may result in an improved outcome compared with standard care. Our results may suggest a causal relationship between suboptimal platelet inhibition and worse outcomes in this selected patient population.
Conclusions:
In low-risk patients according to clinical presentation who had poor responsiveness to standard oral platelet inhibitors via a point-of-care assay, intensified platelet inhibition with tirofiban lowers the incidence of myocardial infarction after elective coronary intervention. 19 
A New Tool for the Risk Stratification of Patients With Complex Coronary Artery Disease: The Clinical SYNTAX Score
Summary: Risk stratification is becoming an increasingly important part of the assessment of patients who are candidates for coronary revascularization. The recently published SYNTAX study indicates that percutaneous coronary intervention disease is only appropriate in a subset of those with complex disease. Patient outcomes were assessed according to the SYNTAX score, which is based on the extent of coronary disease. The absence of patient features has limited the score for risk assessment in everyday practice because the complexity of coronary disease is not the only factor that affects patient risk. The Clinical SYNTAX score combines the SYNTAX score with a simple patient score. The Clinical SYNTAX score improves the predictive ability for the majority of patients undergoing percutaneous coronary intervention and enables a physician to provide an individualized assessment of risk, which is vital for appropriate informed consent. Moreover, the Clinical SYNTAX score can be used to adjust for the differences in case mix between hospitals and individual operators to allow a meaningful comparison of performance.
Conclusions: An improvement in the ability of the SYNTAX Score to predict MACCE and mortality can be achieved by combining the SYNTAX Score with a simple clinical risk score incorporating age, ejection fraction, and creatinine clearance to produce the Clinical SYNTAX score. 20
Unprotected Left Main Stenting in the Real World: Two-Year Outcomes of the French Left Main Taxus Registry
Summary: This was the largest prospective, multicenter, real-world registry of patients with unprotected left main disease who were treated with a paclitaxel-eluting stent with a uniform technical strategy of provisional side-branch T-stenting for distal left main coronary artery disease. The advanced age and the high proportion of bifurcation disease account for the unselected nature of the population. The results obtained at the 2-year follow-up, complete for 99% of patients, illustrate the safety and efficacy of this technique, with a device-oriented major adverse cardiac event rate of 15.8% (including cardiac death in 5.4% and target-lesion revascularization in 8.7% of patients). Particular attention was paid to left main stent thrombosis, with a low rate of definite or probable stent thrombosis according to Academic Research Consortium definitions at 2-year follow-up (0.7%). This study also provides valuable information about clinical outcomes after distal left main stenting, which in the past has been associated with a higher risk of adverse outcomes. Furthermore, this study addresses the important issue of outcomes in patients with left main restenosis, showing that the vast majority of these patients had stable presentations and focal restenosis, treated in the majority of cases by repeat percutaneous coronary intervention with very acceptable outcomes.
Conclusions: Unprotected left main stenting with paclitaxel-eluting stents, with a strategy of provisional side-branch T-stenting for distal lesions, provides excellent acute angiographic results and good midterm clinical outcomes, with a 15.8% rate of major adverse cardiac events at 2-year follow-up. 21
Long-Term Mortality of Patients Undergoing Cardiac Catheterization for ST-Elevation and Non-ST-Elevation Myocardial Infarction
Summary: In this study of outcomes over a median follow-up period of 4 years among a contemporary cohort of patients undergoing cardiac catheterization for ST-elevation myocardial infarction (STEMI; nϭ1974) and non-STEMI (NSTEMI; nϭ2413) at an academic medical center, we compared mortality rates over restricted time intervals and the differential impact of early revascularization on mortality stratified by ST-elevation status. The longterm mortality rates of 29% and 45% for STEMI and NSTEMI, respectively, remain very similar to historical mortality rates among patients with Q-wave and non-Q-wave MI in the era before reperfusion and early invasive therapy, indicating a critical need to develop more efficacious treatment strategies for both types of MI. The adjusted mortality risk was greater for STEMI during the first 2 months (hazard ratio for STEMI versus NSTEMI, 1.85; 95% confidence interval, 1.45-2.38) but greater for NSTEMI after 2 months (hazard ratio for STEMI versus NSTEMI, 0.68; 95% confidence interval, 0.59 -0.83). Compared with late or no revascularization, early revascularization was associated with a lower adjusted risk of long-term mortality for both STEMI (hazard ratio, 0.73; 95% confidence interval, 0.58 -0.90) and NSTEMI (hazard ratio, 0.76; 95% confidence interval, 0.65-0.89) (P for Interac-tionϭ0.22). These data suggest that the relative mortality among patients managed invasively for STEMI and NSTEMI is time dependent, with NSTEMI imparting a delayed but substantial enhancement of mortality risk; moreover, early revascularization may improve very late survival to a similar extent for both infarct types. In clinical investigations of early revascularization among patients with NSTEMI, extended follow-up may therefore be necessary to demonstrate treatment benefit.
Conclusions: Among a contemporary cohort of acute MI patients with significant coronary disease during cardiac catheterization, STEMI was associated with a higher risk of short-term mortality, but NSTEMI was associated with a higher risk of long-term mortality. Early revascularization was associated with a similar improvement in long-term outcomes for both STEMI and NSTEMI. These data suggest that in clinical investigations of early revascularization among patients with NSTEMI, extended follow-up may be necessary to demonstrate treatment benefit. 22
Long-Term Clinical Outcome After Fractional Flow Reserve-Guided Treatment in Patients With Angiographically Equivocal Left Main Coronary Artery Stenosis
Summary: Significant left main coronary artery stenosis is an accepted indication for surgical revascularization. Angiography alone has limited accuracy in assessing actual stenosis severity, and there is great interobserver variability in lesions of the left main coronary artery. Consequently, ambiguous left main coronary artery disease sometimes results in considerable uncertainty as to which therapeutic strategy may be best for the patient. Fractional flow reserve (FFR) can be measured at the time of coronary angiography and identifies coronary lesions responsible for ischemia. Because FFR-guided revascularization strategies are associated with favorable clinical outcomes in patients with single-vessel or multivessel disease, the main goal of this retrospective study was to evaluate the long-term clinical outcome of an FFR-guided revascularization strategy in patients with angiographically equivocal left main coronary artery stenosis. Patients with FFR Ն0.80 were treated medically or percutaneously, and patients with FFR Ͻ0.80 were treated surgically. The 5-year survival and 5-year event-free survival estimates were similar in the 2 groups. Angiographic assessment of the lesions, either by quantitative coronary angiography or by visual estimation, failed to identify the stenosis significance in almost one third of the total patient population. Angiography alone does not allow appropriate individual decision making about the need for revascularization in patients with equivocal left main coronary artery lesions and often underestimates their functional significance. FFR should be assessed in such patients before a decision is made "blindly" about the need for revascularization.
Conclusions:
In patients with equivocal stenosis of the left main coronary artery, angiography alone does not allow appropriate individual decision making about the need for revascularization and often underestimates the functional significance of the stenosis. The favorable outcome of an FFR-guided strategy suggests that FFR should be assessed in such patients before a decision is made "blindly" about the need for revascularization. 23
Adding Cilostazol to Dual Antiplatelet Therapy Achieves Greater Platelet Inhibition than High Maintenance Dose Clopidogrel in Patients With Acute Myocardial Infarction: Results of the Adjunctive Cilostazol versus High Maintenance Dose Clopidogrel in Patients With AMI (ACCEL-AMI) Study
Summary: Because patients with acute myocardial infarction (AMI) have shown enhanced platelet reactivity during the early phase, the standard doses of clopidogrel and aspirin might not achieve adequate platelet inhibition. Furthermore, recent studies have identified that high-postclopidogrel platelet reactivity in these patients has been associated with ischemic clinical events. Based on the premise that intensified antiplatelet therapy in patients with AMI may lead to better ADP-stimulated platelet inhibition and a reduced risk for adverse cardiovascular events, adjunctive cilostazol to dual antiplatelet therapy (or "triple antiplatelet therapy") can be an attractive alternative in patients with AMI. Triple antiplatelet therapy has shown more beneficial effects on platelet inhibition and endothelial senescence than has dual antiplatelet therapy in selected subsets. In this study, we assessed the degree of platelet inhibition by adjunctive cilostazol in patients with AMI. We enrolled patients with AMI treated with drug-eluting stents only, and we assessed platelet reactivity at predischarge and 30-day follow-up. Among these patients, triple antiplatelet therapy resulted in a greater antiplatelet effect than high maintenance dose clopidogrel of 150 mg daily, as demonstrated by various parameters of conventional aggregometry and the VerifyNow P2Y12 assay. Because a common polymorphism of cytochrome P450 (CYP) 2C19 gene is more prominent among East Asians than whites (Ϸ60% versus 30%), high maintenance dose clopidogrel can exhibit much diminished platelet inhibition in East Asians than in whites. Furthermore, cilostazol is mainly converted into active metabolites by CYP3A system, and adjunctive cilostazol can inhibit platelet aggregation consistently irrespective of the carriage of CYP2C19 mutant allele.
Conclusions: Among patients with AMI undergoing coronary stenting, triple antiplatelet therapy results in a greater antiplatelet effect at 30 days as compared with a high-MD clopidogrel or standard dual antiplatelet therapy. 24
Randomized Trial of Simple versus Complex Drug-Eluting Stenting for Bifurcation Lesions: The British Bifurcation Coronary Study: Old, New, and Evolving Strategies
Summary: Treatment of bifurcation coronary lesions generates much debate. The BBC ONE study recruited 500 patients with coronary bifurcation lesions and randomly allocated them to either a simple strategy (main-vessel stenting with or without kissing balloon dilatation/T stenting) or a complex strategy (complete lesion coverage with either crush or culotte stenting plus mandatory kissing balloon dilatation). Clinical follow-up of these 2 groups to 9 months showed an 8% major adverse event rate in the simple group versus a 15% major adverse event rate in the complex group. This difference was largely driven by periprocedural myocardial infarction. The study therefore suggests that the usual strategy for the majority of bifurcation lesions should be the simple provisional strategy and that more complex strategies should be reserved for more complex anatomies, involving perhaps large side branches with significant length ostial side-branch disease.
Conclusions: When coronary bifurcation lesions are treated, a systematic 2-stent technique results in higher rates of in-hospital and 9-month major adverse cardiovascular events. This difference is largely driven by periprocedural myocardial infarction. Procedure duration is longer, and x-ray dose is higher. The provisional technique should remain the preferred strategy in the majority of cases. 25
Previous Coronary Stent Implantation and Cardiac Events in Patients Undergoing Noncardiac Surgery
Summary: Patients treated with coronary stent implantation before undergoing noncardiac surgery seem to be at increased risk for adverse perioperative cardiac events. The period of risk and the influence of stent type on outcome remain to be determined in a large-scale multicenter study. To specifically address these issues, we performed a systematic, large-scale retrospective cohort study in Scotland linking the national angioplasty registry with hospital admission data to examine outcomes in all patients treated with coronary stenting over a 4-year period who subsequently underwent noncardiac surgery (nϭ1953). Approximately 5% of patients underwent noncardiac surgery within 1 year of coronary stent implantation. Perioperative death and ischemic cardiac events were more common when surgery was performed within 6 weeks of stent implantation, especially where revascularization was performed after an acute coronary syndrome. For at least 2 years after coronary stent implantation, no difference in cardiac outcomes after noncardiac surgery was evident according to whether the initial stent was drug eluting or bare metal. Our findings support current guideline recommendations that noncardiac surgery should be deferred for at least 4 to 6 weeks after implantation of a bare-metal coronary stent. Although our findings suggest similar perioperative outcomes for patients treated with drug-eluting stents, further prospective largescale studies are required before any change to the current guideline e748 Circulation December 6, 2011
recommendations that noncardiac surgery be deferred for 6 to 12 months after drug-eluting stent implantation can be supported.
Conclusions:
Patients undergoing noncardiac surgery after recent coronary stent implantation are at increased risk of perioperative myocardial ischemia, myocardial infarction, and death, particularly after an acute coronary syndrome. For at least 2 years after percutaneous coronary intervention, cardiac outcomes after noncardiac surgery are similar for both drug-eluting and bare-metal stents. 26
Thirty-Day Outcomes for Carotid Artery Stenting in 6320 Patients From 2 Prospective, Multicenter, High-Surgical-Risk Registries
Summary: Carotid stenting with embolic protection (carotid artery stenting) was approved by the Food and Drug Administration in 2004 for treatment of carotid artery stenosis in patients at high risk for complications from carotid endarterectomy. Carotid artery stenting is increasingly being used as an alternative treatment modality in high-surgical-risk patients requiring revascularization for stroke prevention. Data are presented from 2 large, rigorously conducted, prospective, Food and Drug Administration-audited, postmarket carotid stenting studies in patients at risk for surgery, treated by a broad group of physicians under commercial use conditions. In total, data on 6320 patients from 280 US sites and 672 operators are included in this analysis, In patients Ͻ80 years old, the combined 30-day rate of death and stroke was 5.3% for symptomatic patients and 2.9% for asymptomatic patients, independent of unfavorable risk factors (anatomic or physiological). These outcomes meet the guideline standards established by the American Heart Association for acceptable 30-day death and stroke rates for patients undergoing standard-surgical-risk carotid endarterectomy: Ͻ6% risk of perioperative stroke and death within 30 days with previous symptoms of nondisabling stroke or transitory ischemic attack, or Ͻ3% risk without previous symptoms. The data reported have not been described previously in a multicenter, prospective assessment of high-surgical-risk patients. The outcomes represent a significant achievement for the practice of carotid artery stenting in real-world conditions and provide an important addition to the data available to physicians weighing the benefits of different treatment modalities.
Conclusions:
Outcomes for carotid artery stenting in nonoctogenarian high-surgical-risk patients have improved since the pivotal Food and Drug Administration approval trials, and have achieved American Heart Association standards in both symptomatic and asymptomatic lesions. 27
Comparative Evaluation of Left and Right Ventricular Endomyocardial Biopsy: Differences in Complication Rate and Diagnostic Performance
Summary: Several recent clinical trials have demonstrated the therapeutic and prognostic benefits of EMB-based diagnoses such as myocarditis and other nonischemic cardiomyopathies. However, EMB is an invasive procedure with a nonnegligible risk of complications, and therefore its clinical use has been controversial. In the present study, the procedural safety and diagnostic performance of selective LV-EMB, selective RV-EMB, or biventricular EMB were comparatively investigated for the first time in patients with suspected myocarditis or nonischemic cardiomyopathy, using state-ofthe-art techniques for sampling of biopsies as well as postprocedural histopathologic workup of specimens. In addition, the role of CMR as a noninvasive tool in diagnosing inflammatory and several noninflammatory cardiomyopathies as well as in guiding EMB was evaluated. Analyses of LV-and/or RV-EMBs in 755 patients revealed a major complication rate for LV-EMB of 0.64% and for RV-EMB of only 0.82%. Thus, both LV-EMB and RV-EMB turned out to be safe procedures. Moreover, on the basis of the results of this study, (1) biventricular biopsies have a higher diagnostic yield compared to selective biopsies and (2) LV-EMB gives a higher diagnostic yield compared to RV-EMB while having a lower risk for minor complications. Finally, there were no substantial differences in the number of positive diagnostic LV-EMBs, RV-EMBs, or biventricular EMBs when related to the site of CMR-based LGE. As suggested by a recently published consensus article for CMR-based diagnosis of myocarditis, the combined use of different CMR protocols for an improved CMR evaluation of myocarditis is recommended.
Conclusions: Both LV-EMB and RV-EMB are safe procedures if performed by experienced interventionalists. The diagnostic yield of EMB may be optimized when samples from both ventricles are available. Preferential biopsy in regions showing late gadolinium enhancement on cardiovascular magnetic resonance does not increase the number of positive diagnoses of myocarditis. 28
Iloprost Prevents Contrast-Induced Nephropathy in Patients With Renal Dysfunction Undergoing Coronary Angiography or Intervention
Summary: Contrast-induced renal vasoconstriction is believed to play a pivotal role in the pathogenesis of contrast-induced nephropathy (CIN). The present study found that prophylactic periprocedural intravenous administration of the prostacyclin analog iloprost at a dose of 1 ng ⅐ kg -1 ⅐ min -1 in patients with renal dysfunction undergoing a coronary procedure reduced the incidence of CIN by Ϸ70% (odds ratio, 0.29; 95% confidence interval, 0.12-0.69; Pϭ0.005). Importantly, the rate of side effects leading to iloprost discontinuation or dose reduction was very low and comparable to that observed in the control group. The important new information provided by this study is the proof of principle that CIN can be prevented by a mechanism distinct from volume expansion or direct antioxidant effects, namely prostacyclin replenishment. Furthermore, the efficacy of iloprost to prevent CIN at the dose studied is noteworthy. The prevention of CIN, which accounts for considerable morbidity and mortality, remains a vexing problem. Although preliminary data, mostly from single studies, have previously suggested that numerous specific pharmaceuticals had a preventive effect, more recent research has failed to confirm their efficacy. With questions lingering, volume expansion remains the only indisputable CIN preventive strategy. In this respect, although the results of this trial appear convincing and support the use of iloprost for efficient prevention of CIN in high-risk patients undergoing a coronary procedure, recommendation for widespread use should await further trial confirmation.
Conclusions: Prophylactic administration of iloprost may protect against contrast-induced nephropathy in high-risk patients undergoing a coronary procedure. 29
A Randomized Controlled Trial of Angiography versus Intravascular Ultrasound-Directed Bare-Metal Coronary Stent Placement (The AVID Trial)
Summary: Much controversy exists regarding the importance of intravascular ultrasound (IVUS) as a method of determining adequate stent placement. Although 2 studies showed a significant benefit of IVUS-guided bare-metal stent placement, others failed to demonstrate a difference when compared with a procedure guided by angiography alone. Because of the heterogeneity of available studies and varying clinical results, the technique of IVUS-guided stent placement was never satisfactorily evaluated, and the controversy never adequately resolved. The present study (A Randomized Controlled Trial of Angiography versus Intravascular Ultrasound-Directed Bare-Metal Coronary Stent Placement [The AVID Trial]) represents the largest multicenter, randomized controlled trial to compare IVUS-directed stent placement with a procedure guided by angiography alone in a real-world setting. The results establish that IVUS-directed therapy using AVID criteria for optimal stent placement, particularly in vessels Ն2.5 mm, improves TLR within the first year after stent placement without an increase in complications. However, in the intention-to-treat analysis, whereas the 12-month TLR rate was lower in the IVUS-directed treatment group compared with the Angiography-directed group, the difference was not statistically significant. The greatest value of IVUS-directed therapy seems to be in vessels Ն2.5 and Ͻ3.25 mm by angiography and in vessels with a prestent angiographic stenosis of Ն70%. In addition, when compared with an experienced IVUS core laboratory, individual operators commonly fail to recognize IVUS findings that may be important for improved clinical outcome. Only 37% of underdilated stents in the IVUS-directed group underwent further therapy in an attempt to optimize the final result.
Conclusions: IVUS-directed bare-metal stent placement results in larger acute stent dimensions without an increase in complications and a significantly lower 12-month TLR rate for vessels Ն2.5 mm by angiography and for vessels with high-grade prestent stenosis. However, for the entire sample analyzed on an intention-to-treat basis, IVUS-directed bare-metal stent placement does not significantly reduce the 12-month TLR rate when compared with stent placement guided by angiography alone. In addition, IVUS evaluation of adequate stent expansion is underutilized by experienced operators. 30
Long-Term Safety and Effectiveness of Unprotected Left Main Coronary Stenting With Drug-Eluting Stents Compared With Bare-Metal Stents
Summary: Although the use of drug-eluting stents (DES) has become a common practice for unprotected left main coronary artery stenosis in certain areas, the uncertainty about the long-term safety and durable efficacy of DES remains. In the present substudy of the largest registry of patients receiving revascularization therapy for unprotected left main coronary artery stenosis, DES showed a comparable 3-year risk of death or myocardial infarction compared with bare metal stents. Moreover, the reduction in target lesion revascularization is sustained in late follow-up to 3 years. Of note is that the incidence of stent thrombosis did not differ between the 2 stent types. The superior benefit of DES over bare metal stents was consistently maintained after rigorous adjustment for different baseline characteristics between the 2 stent groups. With regard to the impact of left main coronary artery location, there was no difference in DES benefit between bifurcation and nonbifurcation lesions. In fact, the use of DES decreased the 3-year risk of target lesion revascularization by 60% with comparable risk of death or myocardial infarction for either bifurcation or nonbifurcation left main coronary artery lesions. This study provides important information on the issue of long-term safety and efficacy of DES for the treatment of unprotected left main coronary artery stenosis.
Conclusions: Compared with bare metal stents, DES were associated with a reduction in the need for repeat revascularization without increasing the risk of death or myocardial infarction for patients with unprotected left main coronary artery stenosis. 31
Intracoronary Eptifibatide Bolus Administration During Percutaneous Coronary Revascularization for Acute Coronary Syndromes With Evaluation of Platelet Glycoprotein IIb/IIIa Receptor Occupancy and Platelet Function: The Intracoronary Eptifibatide (ICE) Trial
Summary: Eptifibatide administered intravenously may improve cardiac outcomes in selected patients during percutaneous coronary intervention. We evaluated the strategy of intracoronary bolus administration of eptifibatide to achieve higher levels of glycoprotein IIb/IIIa receptor occupancy in the local coronary bed, an effect that may disaggregate coronary thrombus and hence improve coronary flow. Platelet glycoprotein IIb/IIIa receptor occupancy in the coronary sinus was significantly greater with intracoronary versus intravenous administration: first bolus, 94Ϯ9% versus 51Ϯ15% (PϽ0.001); second bolus, 99Ϯ2% versus 91Ϯ4% (Pϭ0.001), respectively. Microvascular perfusion was significantly improved as measured by the corrected thrombolysis in myocardial infarction frame count with intracoronary versus intravenous administration: pre-percutaneous coronary intervention, 36 (median) (25th and 75th percentiles, 16 and 64) versus 31 (25th and 75th percentiles, 23 and 45; Pϭ0.8); and post-percutaneous coronary intervention, 18 (25th and 75th percentiles, 10 and 22) versus 25 (25th and 75th percentiles, 22 and 35; Pϭ0.007), respectively. We observed improved efficacy of direct intracoronary administration of eptifibatide as demonstrated by increased local platelet glycoprotein IIb/IIIa receptor occupancy and better microcirculatory flow with an improved corrected thrombolysis in myocardial infarction frame count. This approach requires further study and confirmation of its potential to reduce major adverse cardiac events.
Conclusions: Intracoronary bolus administration of eptifibatide during percutaneous coronary intervention in patients with acute coronary syndromes results in higher local platelet glycoprotein IIb/IIIa receptor occupancy, which is associated with improved microvascular perfusion demonstrated by an improved cTFC. 32
Three-Year Outcomes After Sirolimus-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease: Insights From the j-Cypher Registry
Summary: Despite the growing popularity of stenting unprotected left main coronary arteries with drug-eluting stents, long-term outcomes have not been assessed adequately. This large multicenter registry in Japan (the j-Cypher registry) compared the 3-year clinical outcomes of 582 patients undergoing percutaneous coronary intervention for unprotected left main coronary artery (ULMCA) lesions with those of 12,242 patients undergoing percutaneous coronary intervention for non-ULMCA lesions only. The influence of lesion location and bifurcation stenting strategy on clinical outcomes was also assessed in 476 patients whose ULMCA lesions were treated exclusively with sirolimus-eluting stents. The main findings of this study are as follows: (1) Percutaneous coronary intervention for ULMCA lesions was associated with a higher late mortality rate than for lesions located elsewhere, but this finding was mainly related to factors other than the left main being the treatment site 2 ; sirolimuseluting stent implantation in ostial/shaft left main lesions was associated with a better 3-year target-lesion revascularization rate than in distal bifurcation lesions; and 3 patients with ULMCA plus 3-vessel disease had poor long-term outcome in terms of coronary revascularization, stent thrombosis, and cardiac death. Therefore, although ULMCA stenting with a sirolimus-eluting stent is an attractive option, clinical outcomes are less satisfactory in patients who need bifurcation 2-stent treatment or who have extensive coronary artery disease outside the ULMCA. Consideration of the individual patient's risk stratification is important when selecting coronary revascularization strategies in patients with ULMCA disease.
Conclusions:
The higher unadjusted mortality rate of patients undergoing ULMCA stenting with a sirolimus-eluting stent did not appear to be related to ULMCA treatment itself but rather to the patients' high-risk profile. Although long-term outcomes in patients with ostial/shaft ULMCA lesions were favorable, outcomes in patients with bifurcation lesions treated with stenting of both the main and side branches appeared unacceptable. 33
Immediate Percutaneous Coronary Intervention Is Associated With Better Survival After Out-of-Hospital Cardiac Arrest: Insights From the PROCAT (Parisian Region Out of Hospital Cardiac Arrest) Registry
Summary: For survivors of an out-of-hospital cardiac arrest, the predictive value of the ECG for coronary artery occlusion is poor, and clinical information such as chest pain or risk factors often are lacking. Accordingly, it is difficult to select appropriate patient candidates for early coronary angiography and possible percutaneous intervention. In a tertiary center in Paris, an immediate coronary angiogram was performed in 435 patients with out-of-hospital cardiac arrest with no obvious noncardiac cause of arrest, regardless of ECG pattern. At least 1 significant coronary artery lesion was found in 304 (70%) patients, in 128 of 134 (96%) patients with ST-segment elevation on the ECG performed after the return of spontaneous circulation, and in 176 (58%) of 301 patients without ST-segment elevation. Overall hospital survival rate was 40%. Multivariable analysis showed successful percutaneous intervention to be an independent predictive factor of survival, regardless of the postresuscitation ECG pattern. Immediate percutaneous intervention seems to offer survival benefit in selected patients with out-ofhospital cardiac arrest with no obvious noncardiac cause.
Conclusions: Successful immediate coronary angioplasty is associated with improved hospital survival in patients with or without ST-segment elevation. Therefore, our findings support the use of immediate coronary angiography in patients with out-of-hospital cardiac arrest with no obvious noncardiac cause of arrest regardless of the ECG pattern. 34
Meta-Analyses of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy: Comparative Rates of Overall Mortality and Sudden Cardiac Death After Treatment
Summary: For patients with obstructive hypertrophic cardiomyopathy and symptoms refractory to medical therapy, septal reduction achieved by either surgical myectomy or alcohol septal ablation (ASA) has been shown to reduce the dynamic left ventricular outflow tract obstruction and reduce symptoms of the disease. However, concerns regarding the possibility of scar-mediated ventricular arrhythmias and sudden cardiac death (SCD) after ASA remain. In the absence of randomized trials evaluating these treatments, this study was performed to compare the rates of overall mortality and SCD reported after these septal reduction therapies. Systematic reviews and meta-analyses of observational studies of surgical myectomy and ASA were performed to derive rates of overall mortality and SCD. Compared with patients treated with ASA, patients treated with surgical myectomy were younger, had greater septal wall thickness, and had longer follow-up. Unadjusted all-cause mortality and SCD rates were similarly low after both septal reduction therapies. After adjustment for available baseline characteristics that may influence the rates of these events, ASAtreated cohorts had lower rates of all-cause mortality and SCD than myectomy-treated cohorts. These low rates of overall mortality and SCD after septal reduction may better inform clinical decisions for patients with symptomatic obstructive hypertrophic cardiomyopathy.
Conclusions:
Rates of all-cause mortality and SCD after both ASA and surgical myectomy were similarly low. Adjusted for baseline characteristics, the odds ratios for treatment effect on all-cause mortality and SCD were lower in ASA cohorts compared with surgical myectomy cohorts. 35
Sirolimus-Eluting Stent versus Balloon Angioplasty for Sirolimus-Eluting Stent Restenosis: Insights From the j-Cypher Registry
Summary: Optimal treatment strategies for restenosis of sirolimuseluting stents (SES) have not been adequately addressed yet. A few previous small observational studies compared the use of SES for restenosis of SES with the use of balloon angioplasty (BA) in preventing recurrent target-lesion revascularization (TLR). However, there is no report from either randomized trials or large-scale observational studies investigating the efficacy of SES for restenosis associated with SES use. Our current analysis revealed that cumulative incidence of recurrent TLR in the SES-treated restenosis lesions was significantly lower than that in the BA-treated restenosis lesions (23.8% versus 37.7% at 2 years after the first TLR; PϽ0.0001). Among 33 baseline variables evaluated, only hemodialysis was identified to be the independent risk factor for recurrent TLR by a multivariable logistic regression analysis. After adjusting for confounders, repeated SES implantation was associated with a strong treatment effect in preventing recurrent TLR over BA (odds ratio, 0.44; 95% confidence interval, 0.32-0.61; PϽ0.0001). The 2-year mortality and stent thrombosis rates between the SES-and the BA-treated groups were 10.4% versus 10.8% (Pϭ0.4) and 0.6% versus 0.6%, respectively. Although other modalities like drugeluting balloon catheters might be promising alternatives, our results indicate that repeated implantation of SES for SES-associated restenosis is more effective in preventing recurrent TLR than treatment with BA, without signals suggesting safety concerns. Until otherwise proven by adequately sized randomized trials, our current observation supports the choice of repeated SES implantation for SES-associated restenosis.
Conclusions: Repeated implantation of SES for SES-associated restenosis is more effective in preventing recurrent TLR than treatment with BA, without evidence of safety concerns. 36
Comparison of Inflammatory Response After Implantation of Sirolimus-and Paclitaxel-Eluting Stents in Porcine Coronary Arteries
Summary: The present study compares sirolimus (CYPHER) and paclitaxel (TAXUS) drug-eluting stents implanted in noninjured coronary arteries in domestic swine for 30, 90, and 180 days. There was a much higher prevalence of a diffusely severe inflammatory response with granuloma formation and numerous eosinophils in the CYPHER-stented vessels compared with TAXUS. This distinctive inflammatory pattern, present diffusely through the stented arterial segment and seen repeatedly in the porcine model, has been identified in a small proportion of human autopsy cases involving CYPHER stents in which the diffuse granulomatous inflammation was associated with aneurysmal dilation and thrombosis of the stented coronary artery but to date has been reported in just 1 TAXUS stent with only focal involvement of a few struts. In the porcine coronary artery model, both CYPHER and TAXUS stents were associated with greater para-strut fibrin deposition than their bare metal controls at 30 days, but TAXUS stents showed greater fibrin deposition than CYPHER stents at 30 days persisting through 180 days. As a result of strut deployment in normal arteries combined with rapid smooth muscle cell proliferation and endothelialization in the pig, fibrin deposits were sequestered with the developing neointima and not exposed to flow in both drug-eluting stents. This characteristic of the porcine model limits its translation to the clinical issue of delayed thrombosis with drug-eluting stents. The porcine model does produce the severe, granulomatous inflammatory response seen in humans, but the true prevalence of this response in humans is unknown at this time.
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Conclusions: Although these data cannot be directly extrapolated to humans, the high prevalence in this porcine model of diffuse granulomatous inflammation seen with CYPHER stents, persisting at 180 days and associated with extensive remodeling of the artery, and persistent para-strut fibrin deposition with TAXUS stents emphasize the need for further investigation of biocompatibility with these and other novel combination drug/polymer drug-eluting stents. 37
Long-Term Clinical Outcome After a First Angiographically Confirmed Coronary Stent Thrombosis: An Analysis of 431 Cases
Summary: Stent thrombosis is a rare but serious complication after percutaneous coronary intervention. In the present study, the longterm clinical outcome of 431 consecutive patients who experienced an angiographically confirmed (definite) stent thrombosis was evaluated. The primary end point was the composite of cardiac death and definite recurrent stent thrombosis, which occurred in 111 patients after a median follow-up of 27.1 month. The cumulative Kaplan-Meier estimates of definite recurrent stent thrombosis, definite or probable recurrent stent thrombosis, any myocardial infarction, and any target-vessel revascularization were 18.8%, 20.1%, 21.3%, and 32.0%, respectively, at the longest available follow-up. Multivariate analysis identified that implantation of an additional coronary stent at the first stent thrombosis was associated with unfavorable outcome, in addition to other established predictors such as diabetes mellitus, total stent length, severe calcification, American College of Cardiology/American Heart Association B2-C lesions, TIMI (Thrombolysis In Myocardial Infarction) flow grade Ͻ3 after percutaneous coronary intervention, and left ventricular ejection fraction Ͻ45%. Recurrent stent thrombosis is not an infrequent event after a first stent thrombosis, and randomized trials are urgently needed to determine the optimal treatment strategy in patients with a first stent thrombosis.
Conclusions:
The long-term clinical outcome after a first definite stent thrombosis is unfavorable, with a high mortality and recurrence rate. Diabetes mellitus, left ventricular ejection fraction Ͻ45%, long total stent length, complex coronary lesions, TIMI flow grade Ͻ3 after percutaneous coronary intervention, and implantation of an additional coronary stent during the emergent percutaneous coronary intervention for the ST were associated with this unfavorable outcome. 38
Double versus Single Stenting for Coronary Bifurcation Lesions: A Meta-Analysis
Summary: The ideal approach to percutaneous coronary intervention of bifurcation lesions has not been established. Double stenting of both main and side branches produces attractive postprocedural angiographic results and several techniques for successful deployment have been described. Randomized trials published so far have not detected any clinical benefit with the deployment of an additional stent on the side branch, but they were of limited sample size to allow robust conclusions. A meta-analysis of 6 studies involving 1642 patients did not detect any difference in mortality and target lesion revascularization between the 2 approaches. However, there was an increased risk of myocardial infarction and probably stent thrombosis with double stenting. This indicates that a procedure that entails extra costs and irradiation time for both physicians and patients does not confer any real benefit; on the contrary, it can increase the risk of potential complications. Occluded side branches are usually clinically silent, and the majority of them reappears at follow-up and probably do not affect long-term clinical event-free survival. In this context, the results of the meta-analysis clearly suggest that, in most cases, stenting of the side branch should be avoided.
Conclusions: Stenting of both the main vessel and side branch in bifurcation lesions may increase myocardial infarction and stent thrombosis risk compared with stenting of the main vessel only. 39
Effect of Supersaturated Oxygen Delivery on Infarct Size After Percutaneous Coronary Intervention in Acute Myocardial Infarction
Summary: Primary percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction has become widely accepted as the preferred reperfusion modality because of its high success rate in restoring patency of the occluded infarct artery, with resultant low rates of death, reinfarction, recurrent ischemia, and stroke. Nonetheless, myocardial salvage is often suboptimal in many patients after primary PCI, in part because of late presentation and also because of microcirculatory dysfunction and reperfusion injury. The intracoronary delivery of supersaturated oxygen with a PaO2 of 760 to 1000 mm Hg into the coronary artery supplying the myocardial infarct zone for 90 minutes after successful primary PCI has been shown in preclinical models to markedly enhance myocardial recovery. In the randomized AMIHOT-I and AMIHOT-II trials, this therapy was compared with primary PCI without intracoronary infusion in a total of 406 patients with anterior ST-segment elevation myocardial infarction reperfused by successful PCI within 6 hours of symptom onset. Compared with control, SSO2 resulted in a significantly smaller infarct size at 14 days as measured by tc-99m-sestamibi single-photon emission computed tomography imaging, with noninferior rates of major adverse cardiovascular events at 30 days. The benefit in terms of infarct size reduction was particularly profound in patients with the largest infarctions (baseline left ventricular ejection fraction Ͻ40%), in whom an incremental 10% salvage of the left ventricular myocardium was noted. As such, supersaturated oxygen represents the first adjunctive therapy demonstrated in a pivotal trial to reduce infarct size when used in concert with a mechanical reperfusion strategy in ST-segment elevation myocardial infarction.
Conclusions: Among patients with anterior ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention within 6 hours of symptom onset, infusion of Supersaturated Oxygen into the left anterior descending artery infarct territory results in a significant reduction in infarct size with noninferior rates of major adverse cardiovascular events at 30 days. 40
Adjunctive Thrombectomy for Acute Myocardial Infarction: A Bayesian Meta-Analysis
Summary: Device-based removal of thrombus from the infarctrelated artery (adjunctive thrombectomy) during primary percutaneous coronary intervention for acute myocardial infarction (MI) has been the object of increasing interest. Devices can be classified on the basis of their mechanism of action. Suction of the thrombus into a catheter is termed aspiration thrombectomy, whereas mechanical thrombectomy refers to clot fragmentation before aspiration of debris. Aspiration thrombectomy is more simple to perform, and a recent pooled analysis suggested that these less bulky devices have a mortality benefit compared with mechanical devices. In this Bayesian meta-analysis, we tested whether thrombectomy with any device or with an aspiration device leads to better myocardial perfusion and clinical outcomes. Bayesian methods, unlike standard methods, are able to provide inferences of direct clinical utility, such as the probability that 1 intervention is better than another. We found that thrombectomy yielded substantially less no reflow, more STsegment resolution Ն50%, and more thrombolysis in myocardial infarction myocardial perfusion grade 3. Thrombectomy may be 1 of the few preventive measures against no reflow, for which treatments are limited once it is established. However, there was no evidence for a decrease in 30-day post-MI death, death, recurrent MI, or stroke. Moreover, aspiration thrombectomy devices did not lead to substantially better results. It remains possible that a benefit from thrombectomy emerges Ն6 months after MI. Further data on long-term clinical effects of thrombectomy are needed to justify a liberal use of e752 Circulation December 6, 2011 these costly devices in primary percutaneous coronary intervention. The superiority of aspiration devices remains controversial.
Conclusions:
In this Bayesian meta-analysis, adjunctive thrombectomy improves early markers of reperfusion but does not substantially effect 30-day post-MI mortality, reinfarction, and stroke. The use of aspiration thrombectomy devices is not associated with a reduction in post-MI clinical outcomes. Thrombectomy is one of the rare effective preventive measures against no-reflow. 41 
Drug-Eluting Stent Thrombosis in Routine

Background, Incidence, and Predictors of Antiplatelet Therapy Discontinuation During the First Year After Drug-Eluting Stent Implantation
Summary: All guidelines agree on the need for at least 1 year of double-antiplatelet therapy after drug-eluting stent implantation. Our study, conducted in 29 hospitals, shows that 14.4% of 1622 patients receiving drug-eluting stents interrupted at least 1antiplatelet drug for at least 5 consecutive days during the first year after implantation. Although antiplatelet therapy discontinuation (ATD) can be justified by the occurrence of major hemorrhage or surgical procedure, these events occurred in only 25.7% of ATD cases. The most common scenarios for ATD were minor hemorrhages/procedures, medical decisions without any bleeding or bleeding-risk event, and patient initiative. Several patient characteristics predicted higher risk for ATD; some were associated with future bleeding events or the need for invasive procedures, whereas others were associated with ATD due to patient initiative. Although these determinants are not modifiable, they emphasize the need for careful patient selection. Other determinants were related to the process of care. Thus, long-term use of anticoagulants predicted ATD due to medical decision, whereas simple provision of written instructions about the importance of antiplatelet maintenance may avoid some cases of unjustified ATD. These results highlight that medical patterns of care of patients with drug-eluting stents should be better defined, particularly relative to the maintenance of antiplatelet therapy during procedures. In addition, they illustrate a common dilemma in contemporary medicine as a whole, not just in cardiology: Patients who are cared for by their general practitioners may pose formidable dilemmas to such practitioners because of the subtleties of the therapeutic technology used by different specialists.
Conclusions: ATD during the first year after drug-eluting stent implantation is based mainly on patient decision or a medical decision not associated with major bleeding events or major surgical procedures. Individual-and hospital-level variables are important to predict ATD. 43 
A Comparison of Abciximab and Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Primary Percutaneous Coronary Intervention: A Meta-Analysis of Contemporary Randomized Controlled Trials
A Pilot Study of Rapid Cooling by Cold Saline and Endovascular Cooling Before Reperfusion in Patients With ST-Elevation Myocardial Infarction
Summary: The use of endovascular hypothermia in awake patients with acute myocardial infarction has previously been evaluated in the clinical trials ICE-IT and COOL-MI. The trials failed to show a benefit of hypothermia in reducing infarct size. A major problem was that the induction of hypothermia was too slow and only a minority of patients reached target temperature before reperfusion (percutaneous coronary intervention). In this pilot study, a combination of an infusion of cold saline with an endovascular cooling catheter was evaluated in awake patients with acute myocardial infarction. All patients reached a core body temperature of Ͻ35°C without any significant delay in reperfusion therapy, and no increase in heart failure or pulmonary congestion was observed as the result of the hypothermia therapy. Furthermore, a significant reduction in infarct size and Troponin-T levels was observed. Although these promising results must be verified in a larger trial, hypothermia may be a promising candidate for adjunct therapy to revascularization in patients with acute myocardial infarction.
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Conclusions: The protocol demonstrates the ability to reach a core body temperature of Ͻ35°C before reperfusion in all patients without delaying primary percutaneous coronary intervention and that combination hypothermia as an adjunct therapy in acute myocardial infarction may reduce infarct size at 3 days as measured by MRI. 45
Increased Risk of Bleeding in Patients on Clopidogrel Therapy After Drug-Eluting Stents Implantation: Insights From the HMO Research Network-Stent Registry (HMORN-Stent)
Summary: Recent studies have suggested that prolonged dual antiplatelet therapy (_6 months) after drug eluting stent placement may be associated with reduced risk of myocardial infarction and death. As a result, many clinicians have extended treatment with clopidogrel to exceed 12 months and even 18 months. However, clopidogrel use has also been associated with treatment related risks such as bleeding complications. Therefore, to consider the appropriate length of clopidogrel therapy, the risks and benefits must be weighed within a patient population. Accordingly, using the HMO Research Network-Stent Registry, we assessed the association between clopidogrel use and risks of major bleeding to the benefit of decreased myocardial infarction or death in 6-month intervals after discharge. Clopidogrel use was determined by pharmacy dispensing data. After adjustment, patients on clopidogrel therapy was associated with increased major bleeding in all time intervals (0 -6 months, 7-12 months, and 13-18 months) compared with patients off clopidogrel. In contrast, clopidogrel use was also associated with a decreased risk of myocardial infarction for all time intervals and decreased death in the 7-to 12-month interval. These results illustrate the risks and benefits associated with clopidogrel use in routine clinical practice and highlight the importance of identifying which patient subgroups are most likely to benefit from extended clopidogrel therapy and which are most likely to be harmed.
Conclusions:
Clopidogrel use was associated with increased major bleeding and decreased myocardial infarction persisting to 18 months. Bleeding risks on clopidogrel therapy deserve consideration in the ongoing debate regarding optimal clopidogrel duration after percutaneous intervention. 46
Percutaneous Closure of Atrial Septal Defects: Echocardiographic and Functional Results in Patients Older Than 60 Years
Summary: This clinical study on interventional closure of atrial septal defects in patients older than 60 years could demonstrate relief of symptoms, improvement of functional capacity, and positive right-heart remodeling in the echocardiographic analysis. Especially in patients with high shunt volume, the exercise capacity improved significantly. This procedure can be performed with minimal acute and long-term risk, and the authors recommend interventional atrial septal defects closure in this age group.
Conclusions: Percutaneous atrial septal defects closure can be performed safely and with minimal risk even in elderly patients. They profit in terms of symptom reduction, improvement of exercise capacity, and right-heart remodeling. 47
Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes
Summary: The first generation of the bioresorbable everolimus drug-eluting vascular scaffold showed signs of shrinkage at 6 months, which largely contributed to late luminal loss. To maintain the mechanical integrity of the device up to 6 months, the scaffold design and manufacturing process of its polymer were modified. Forty-five patients successfully received a second-generation bioresorbable everolimus drug-eluting vascular scaffold. One patient had postprocedural release of myocardial enzyme without Q-wave occurrence; 1 patient was treated 1 month later with a metallic drug-eluting stent. At the 6-month follow-up, quantitative coronary angiography disclosed 1 edge restenosis (in-segment binary restenosis, 2.4%). The backscattering of the polymeric struts did not decrease over time; the scaffold area was reduced by only 2.0% with intravascular ultrasound, and no change was noted with optical coherence tomography. The late lumen loss amounted to 0.19Ϯ0.18 mm with a limited relative decrease in minimal luminal area of 5.4% on intravascular ultrasound. Optical coherence tomography showed at follow-up that 96.8% of the struts were covered and that malapposition was detected at follow-up in only 3 scaffolds. Mean neointimal growth measured by optical coherence tomography between and on top of the polymeric struts equaled 1.25 mm2, or 16.6% of the scaffold area. A modified manufacturing process of the polymer and geometric changes in the polymeric platform have substantially improved the medium-term performance of the new generation of drug-eluting scaffold, making it comparable to that of current drug-eluting stents. The results constitute proof of concept that this device can adequately revascularize coronary vessels and prevent restenosis.
Conclusions: Modified manufacturing process of the polymer and geometric changes in the polymeric platform have substantially improved the medium-term performance of this new generation of drug-eluting scaffold to become comparable to those of current drug eluting stents. 48
One-Year Clinical Outcomes, Midterm Survival, and Predictors of Mortality After Carotid Stenting in Elderly Patients
Summary: Carotid stenting (CS) is increasingly performed as a method of carotid revascularization. CS has been shown to be noninferior compared with carotid endarterectomy in high-surgicalrisk patients. The Carotid Revascularization Endarterectomy versus Stent Trial (CREST) lead-in phase showed that octogenarians had a markedly elevated 30-day periprocedural stroke or death rate compared with nonoctogenarians that was independent of other factors. Several registries and single-center studies have also reported increased adverse events in this elderly group. Recent reports suggest, however, that CS can be performed in octogenarians with low complication rates. Our previous study showed that CS performed by experienced operators in carefully selected patients resulted in event rates that were within the American Heart Association guidelines for both symptomatic and asymptomatic patients. However, it remains uncertain whether elderly patients, particularly the asymptomatic subgroup, will benefit because, in addition to periprocedural risks, longevity after revascularization is an important consideration. Symptomatic patients derive benefit from carotid revascularization within 2 years, whereas asymptomatic patients require 5 years. No data on survival or predictors of mortality after CS in elderly patients are available. This study demonstrates that a high proportion (85%) of appropriately selected elderly patients survive 2 years and Ͼ75% survive at least 3 years after CS. Thus, CS can be considered a revascularization option in most elderly patients. Better patient selection using the predictors of mortality identified may help to optimize the likelihood of survival and to reduce unwarranted procedures. Larger studies are warranted to determine long-term survival, to further identify predictors of mortality, and to validate the role of stenting in the elderly.
Conclusions: This study demonstrates that in selected elderly patients, a high proportion (85%) survived 2 years and Ͼ75% survived 3 years after stenting. Carotid stenting may be considered a revascularization option in such patients. Better selection of patients using Our findings suggest that a market-oriented financing approach such as that in NYS will lead to much greater use of percutaneous coronary intervention procedures for more discretionary indications (eg, in patients without acute myocardial infarction) but also will provide better access to emergency cardiac invasive procedures.
Conclusions:
The market-oriented financing approach in NYS is associated with markedly higher rates of PCI procedures for both discretionary indications (eg, PCI in nonacute myocardial infarction patients) and emergent indications (eg, primary PCI) compared with the government-funded single-payer system in Ontario. 50
Nitinol Stent Implantation versus Balloon Angioplasty for Lesions in the Superficial Femoral Artery and Proximal Popliteal Artery: Twelve-Month Results From the RESILIENT Randomized Trial
Summary: There is uncertainty regarding the optimal endovascular treatment strategy for patients with lifestyle-limiting claudication and disease in the superficial femoral artery. Previous clinical trials have demonstrated conflicting data regarding the benefits of stenting compared with balloon angioplasty for lesions in this location. There continue to be concerns about the potential for superficial femoral artery stent fracture. The RESILIENT (Randomized Study Comparing the Edwards Self-ExpandIng Lifestent versus Angioplasty Alone In LEsions INvolving The SFA and/or Proximal Popliteal Artery) trial compared the safety and efficacy of a self-expanding nitinol stent to balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery. In RESILIENT, 206 patients were randomly assigned to stent implantation versus balloon angioplasty (2:1 randomization). Stenoses or occlusions up to 15 cm in length could be treated. The acute angiographic results were better after stenting, and at 12-months, primary patency rate was significantly higher in the stent group. There was a reduced need for target lesion revascularization after stenting. The rate of stent fracture was low (3.1%), and none of these stent fractures were associated with adverse clinical consequences. In this multicenter, randomized trial, stenting with a self-expanding nitinol stent was superior to balloon angioplasty for moderate-length lesions in the superficial femoral artery and proximal popliteal artery.
Conclusions: In this multicenter trial, primary implantation of a self-expanding nitinol stent for moderate-length lesions in the superficial femoral artery and proximal popliteal artery was associated with better acute angiographic results and improved patency compared with balloon angioplasty alone. 51
C-Reactive Protein and the Risk of Stent Thrombosis and Cardiovascular Events After Drug-Eluting Stent Implantation
Summary: High-sensitivity C-reactive protein (CRP) has been postulated to be a hemostatic risk factor predicting atherothrombosis. However, the association between CRP and stent thrombosis after drug-eluting stent implantation has not been defined. We prospectively investigated whether CRP levels were associated with the risk of stent thrombosis and long-term clinical outcomes and assessed the incremental usefulness of CRP for predicting these events beyond clinical and angiographic risk assessment in 2691 patients who received drug-eluting stent implantation with a median follow-up of 3.9 years. In multivariable Cox proportional-hazards models, elevated levels of CRP were significantly associated with increased risk of stent thrombosis (definite or probable; hazard ratio, 3.86; 95% confidence interval, 1.82-8.18; PϽ0.001). There were also independent associations of elevated CRP levels with late stent thrombosis (hazard ratio, 3.88; 95% confidence interval, 1.75-8.61; PϽ0.001). Elevated CRP levels significantly predicted the risks of death (hazard ratio, 1.61; 95% confidence interval, 1.13-2.28; Pϭ0.008), myocardial infarction (hazard ratio, 1.63; 95% confidence interval, 1.25-2.12; Pϭ0.001), and death or MI (hazard ratio, 1.61; 95% confidence interval, 1.29 -2.00; PϽ0.001). The incorporation of CRP into a model with patient, lesion, and procedural factors resulted in a significant increase in the C statistic for the prediction of stent thrombosis, myocardial infarction, and the composite of death or myocardial infarction. Our data support the independent association of CRP with stent thrombosis and major cardiovascular events in patients receiving drug-eluting stents. Inflammatory risk assessment with CRP as an adjunct to clinical and angiographic risk factors may be useful for identifying patients at high risk who could then be targeted for preventive measure
Conclusions: Elevated CRP levels were significantly associated with increased risks of stent thrombosis, death, and MI in patients receiving drug-eluting stents, suggesting the usefulness of inflammatory risk assessment with CRP. Given the relatively infrequent occurrence of stent thrombosis, death, and MI, larger studies with longer-term follow-up are required to confirm the novel relationship. 52
Stent Thrombosis in Sweden: A Report From the Swedish Coronary Angiography and Angioplasty Registry
Summary: Coronary stenting reduces the rate of clinical and angiographic restenosis. Stent thrombosis (ST) is an infrequent event after percutaneous coronary interventions but remains a serious complication in terms of morbidity and mortality. The aim of this study was to assess incidences and predictors of ST after percutaneous coronary intervention in the Swedish Coronary Angiography and Angioplasty Registry, provides data from an entire country with complete and continuous registration of all deaths and all repeat angiographies and percutaneous coronary interventions. During the 26-month-long observation period, ST was registered in 882 of 73 798 stents. Acute coronary syndromes, insulin-treated diabetes mellitus, smoking, previous coronary intervention, warfarin treatment, small stent diameter, and stenting in restenotic, complex, or bypass graft lesions had the strongest association with ST in a multivariable statistical model. There were considerable differences in the frequency of ST
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between different stent brands. The overall risk of ST was lower in drug-eluting stents compared with bare metal stents. However, from 6 months after stent implantation and onward the risk for ST was higher in drug-eluting stents compared with bare metal stents. Our findings highlight the need for prospective randomized studies with head-to-head comparisons between different stents.
Conclusions: ST is a multifactor disease, and the incidence varies considerably between patients based on clinical, vessel, and stent characteristics. For drug-eluting stents compared with bare metal stents, the risk pattern was biphasic; initially, bare metal stents demonstrated a higher risk of ST; whereas after the first months, ST risk was higher with drug-eluting stents. Our findings highlight the need for prospective randomized studies with head-to-head comparisons between different stents. 53
Effect of High-Dose Intracoronary Adenosine Administration During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: A Randomized Controlled Trial
Summary: Primary percutaneous coronary intervention (PCI) is the preferred treatment to achieve reperfusion of the infarct-related coronary artery in patients with ST-elevation myocardial infarction. However, impaired myocardial perfusion is often seen after primary PCI. Previous studies have suggested that the administration of intravenous adenosine may improve myocardial perfusion and reduce infarct size. The effect of intracoronary adenosine during primary PCI has not been investigated in a large randomized trial. In this study, 448 consecutive patients presenting with ST-elevation myocardial infarction were randomized to 2 bolus injections of intracoronary adenosine (2x120 g in 20 mL NaCl) or placebo (2x20 mL NaCl). The first bolus injection was given after thrombus aspiration and the second after stenting of the infarct-related artery.
The administration of intracoronary adenosine as adjunctive therapy during primary PCI did not result in an improvement of myocardial perfusion, as assessed on coronary angiogram (myocardial blush grade) and ECG (ST-segment elevation resolution and residual ST-segment deviation), or enzymatic infarct size. No myocardial perfusion effect could be measured directly after infusion of adenosine or placebo, suggesting that no endothelial-dependent vasodilatory reserve is present during myocardial ischemia and reperfusion by PCI. In addition, the contemporary treatment of patients with ST-elevation myocardial infarction, including the systematic performance of thrombus aspiration and the administration of abciximab, may have left limited opportunities for further improvement of myocardial perfusion. Therefore, for further improvement of outcome after primary PCI for ST-elevation myocardial infarction, we should focus on pharmacological therapies with other modes of action.
Conclusions:
In this randomized placebo controlled trial enrolling 448 patients with ST-elevation myocardial infarction, administration of intracoronary adenosine after thrombus aspiration and after stenting of the infarct-related artery did not result in improved myocardial perfusion. 54
Intracoronary Optical Coherence Tomography and Histology at 1 Month and 2, 3, and 4 Years After Implantation of Everolimus-Eluting Bioresorbable Vascular Scaffolds in a Porcine Coronary Artery Model: An Attempt to Decipher the Human Optical Coherence Tomography Images in the ABSORB Trial
Summary: Alterations of the reflectance characteristics of the everolimus-eluting bioresorbable vascular scaffold struts have been reported in humans. However, in the absence of histology, the interpretation of the appearances of the struts by optical coherence tomography (OCT) remains speculative. In the present animal study, the bioresorbable vascular scaffold (3.0x12.0 mm) was implanted in the coronary arteries of pigs that underwent OCT and then were examined by histology immediately or at 28 days or 2, 3, or 4 years after implantation. To assess the biodegradation, gel permeation chromatography was performed. At 2 years, OCT showed that 80.4% of the strut sites had a box-shaped appearance. On histology, these structures were composed of proteoglycan. By gel permeation chromatography, the polymeric material of bioresorbable vascular scaffold was no longer quantifiable, suggesting complete bioresorption. At 3 years, by OCT, most struts showed dissolved appearances (dissolved black, 43.7%; dissolved bright, 34.8%). Histology showed connective tissue cells within a proteoglycan-rich matrix, signifying the beginning of the integration process. At 4 years, only a few struts were recognizable by OCT, and on histology, struts indiscernible by OCT are also minimally detectable, which suggests complete integration. In summary, despite their defined appearance by OCT, struts at 2 years were largely bioresorbed, and at 4 years, struts indiscernible by OCT corresponded well to the completely integrated struts.
OCT might be more sensitive to assess the integration process rather than the polymer alteration. This animal study will potentially serve as a guide for interpretation of OCT after bioresorbable vascular scaffold implantation in the clinical setting.
Conclusions: Struts that are still discernible by OCT at 2 years are compatible with largely bioresorbed struts, as demonstrated by histological and gel permeation chromatography analysis. At 3 and 4 years, both OCT and histology confirm complete integration of the struts into the arterial wall. 55
High Residual Platelet Reactivity After Clopidogrel Loading and Long-Term Clinical Outcome After Drug-Eluting Stenting for Unprotected Left Main Coronary Disease
Summary: There is growing evidence that in vitro high residual platelet reactivity after a loading dose of clopidogrel is a strong marker of the risk of stent thrombosis. This study assessed the impact of high residual platelet reactivity after a clopidogrel loading on clinical outcome in 215 patients undergoing drug-eluting stent implantation for unprotected left main disease. The study shows that high residual platelet reactivity is the only independent predictor of stent thrombosis and cardiac death at long-term follow-up, whereas other variables such as left main bifurcation, number of stents, completeness of revascularization, and surgical risk are not related to stent thrombosis and cardiac death. Patients with high residual platelet reactivity had a nearly 4-fold increase in the risk of stent thrombosis and cardiac death compared with patients with low residual platelet reactivity. The cardiac mortality rate in patients with high residual platelet reactivity continues to increase during longterm follow-up, and this finding suggests a persistent increased risk of thrombotic events despite most of these patients receiving a long-term double dose of clopidogrel or shifting to ticlopidine. It is unknown whether high residual platelet reactivity after clopidogrel loading will remain a marker of increased risk of drug-eluting stent thrombosis and more generally of thrombotic events also using new potent antiplatelet agents. Meanwhile, routine assessment of in vitro residual platelet reactivity to a 600-mg loading dose of clopidogrel in patients with unprotected left main disease potentially suitable for drug-eluting stenting should be considered to guide patient care decisions. 
Conclusions
Stent Parameters Predict Major Adverse Clinical Events and the Response to Platelet Glycoprotein IIb/IIIa Blockade: Findings of the ESPRIT Trial
Summary: This article describes a posthoc analysis of the 1,963 patients who underwent stent implantation in the ESPRIT trial, analyzing the relationships between stent parameters (length, diameter, and stented vessel area) and major adverse clinical events (MACE) at 48 hours and 1 year. Near-linear "dose-responses" were identified between both total implanted length of stent and stented vessel area with MACE in the placebo arm. Eptifibatide substantially flattened the slope of the dose-response curve, with outcomes significantly improved only in those groups with higher MACE event rates. The potential clinical impacts of this article are several. First, the findings suggest that a novel, yet quite straightforward construct exists for predicting complications of stent PCI. Specifically, MACE rates correlate directly with total stented vessel areathe greater the amount of stent implanted, the more likely an adverse event. Second, the analyses identified specific parameters that might be useful, in a dichotomous fashion, for deciding whether or not to administer adjunctive platelet GP IIb/IIIa blockade during a PCI procedure. Treatment was beneficial when the total length of implanted stent was 18 mm or greater (and conversely, there was no benefit at stent lengths Ͻ18 mm). This simple parameter may thus provide additional guidance to the interventional cardiologist for the appropriate application of antithrombotic therapies. However, longer-term follow-up of both of these trials showed that the rates of ipsilateral stroke were low and similar between the 2 groups at 2 and 4 years of follow-up. Similarly, in the recently published Carotid Revascularization Endarterectomy versus Stenting Trial (CREST), the long term outcomes were similar. There is thus a need for extended duration of follow-up in studies comparing carotid artery stenting and carotid endarterectomy.
Conclusions
Conclusions:
In a real-world cohort of patients with a history of carotid artery revascularization, coronary artery stenting was comparable to carotid endarterectomy for late outcomes. 58
Incidence, Mechanisms, Predictors, and Clinical Impact of Acute and Late Stent Malapposition After Primary Intervention in Patients With Acute Myocardial Infarction: An Intravascular Ultrasound Substudy of the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial
Summary: The prognosis for patients with acute myocardial infarction has been improved by primary percutaneous coronary intervention, especially the implantation of bare-metal stents (BMS) or drug-eluting stents. However, there is an increased frequency of late stent malapposition after drug-eluting stent implantation. In the prospective, multicenter Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial, patients with ST-elevation myocardial infarction within 12 hours of symptom onset were randomized 3:1 to TAXUS EXPRESS paclitaxel-eluting stents (PES) versus EXPRESS BMS. The present intravascular ultrasound substudy included 241 patients with 263 native coronary lesions (201 PES, 62 BMS) with poststenting and 13-month follow-up intravascular ultrasound imaging. Postintervention acute stent malapposition occurred in 34.3% PESand 40.3% BMS-treated lesions. The reason for resolved acute stent malapposition was negative remodeling with larger acute stent malapposition areas (Ͼ1.2 mm 2 ) separating persistent from resolved acute stent malapposition. At follow-up, a higher frequency of late stent malapposition was detected in PES-treated lesions (46.8%) mainly because of more late acquired stent malappositions (30.8%) compared with BMS-treated lesions. Late acquired stent malapposition was attributable to plaque/thrombus resolution in both BMS and PES and to positive remodeling in PES; the largest areas of late stent malapposition either persisted from implantation or were seen in lesions with positive remodeling. However, the number of events related to stent malapposition was small (with no deaths or stent thrombosis), and follow-up was limited to only 1 year; therefore, longer follow-up is required to determine the relationship of longterm major adverse cardiac events (and especially very late stent thrombosis) and late stent malapposition.
Conclusions: The incidence of acute stent malapposition (ASM) was similar in PES-and BMS-treated lesions, but late acquired stent malapposition was more common in PES-treated lesions. The reason for resolved ASM was negative remodeling, with larger ASM areas separating persistent from resolved ASM. Late acquired stent malapposition was due mainly to positive remodeling and plaque/thrombus resolution. 59
Outcomes for Patients With ST-Elevation Myocardial Infarction in Hospitals With and Without Onsite Coronary Artery Bypass Graft Surgery: The New York State Experience
Summary: The benefit of primary percutaneous coronary interventions (P-PCI) for patients with ST-elevation myocardial infarction (STEMI) has been well documented. However, controversy still exists as to whether PCI should be expanded to hospitals without coronary artery bypass graft surgery. In this study, patients who were discharged after PCI for STEMI between January 1, 2003, and December 12, 2006, in P-PCI centers (hospitals with no coronary artery bypass graft surgery and PCI only for patients with STEMI) were propensity matched with patients in full service centers, and mortality and subsequent revascularization rates were compared. There were no differences for in-hospital/30-day mortality (2.3% for P-PCI centers versus 1.9% for full service centers [Pϭ0.40]), emergency coronary artery bypass graft surgery (0.06% versus 0.35%, Pϭ0.06), in 3-year mortality (7.1% versus 5.9%, Pϭ0.07) or subsequent revascularization (23.8% versus 21.5%, Pϭ0.52). P-PCI centers had a lower same/next day coronary artery bypass graft rate
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(0.23% versus 0.69%, Pϭ0.046) and higher repeat target vessel PCI rates (12.1% versus 9.0%, Pϭ0.003). For patients with STEMI who did not undergo PCI, P-PCI centers had higher in-hospital mortality (28.5% versus 22.3%; adjusted odds ratio, 1.38; 95% CI, 1.08 -1.75).
In conclusion, no differences between P-PCI centers and full service centers were found in in-hospital/30-day mortality, the need for emergency surgery, 3-year mortality or subsequent revascularization, but P-PCI centers had higher repeat target vessel PCI rates and higher mortality rates for patients who did not undergo PCI. P-PCI centers should be monitored very closely, including the monitoring of patients with STEMI who did not undergo PCI.
Conclusions:
No differences between P-PCI centers and full service centers were found in in-hospital/30-day mortality, the need for emergency surgery, 3-year mortality or subsequent revascularization, but P-PCI centers had higher repeat target vessel PCI rates and higher mortality rates for patients who did not undergo PCI. P-PCI centers should be monitored closely, including the monitoring of patients with STEMI who did not undergo PCI. 60
Intravascular Ultrasound Classification of Plaque Distribution in Left Main Coronary Artery Bifurcations: Where Is the Plaque Really Located?
Summary: Using gray-scale intravascular ultrasound, we assessed 140 left main coronary artery (LMCA) bifurcations with moderate to severe disease, evaluating the longitudinal and circumferential distributions of atherosclerotic plaques with the main purpose to establish the first intravascular ultrasound classification of distal LMCA bifurcation lesions and to provide better insight into the pathology of the LMCA bifurcation. Extending the system proposed by Medina et al, our scheme illustrates 7 types of longitudinal plaque distribution with detailed explanation regarding the spatial orientation toward the myocardium, pericardium, or lateral wall of the vessels. In general, this analysis shows more extensive axial plaque distribution from the LMCA into the ostial/proximal left anterior descending and left circumflex arteries than is apparently angiographically and consistent sparing of the carina. However, despite angiographic assessment and irrespective of standard angiographic and intravascular ultrasound morphologies, 90% of distal LMCA bifurcations fit 1 of 3 patterns: LMCA disease extending into the left anterior descending and left circumflex arteries; LMCA disease extending into the left anterior descending but not the left circumflex artery; and LMCA disease extending into the left anterior descending artery with focal disease at the ostium of the left circumflex artery. We hope that this proposed scheme may help to establish that preinterventional coronary morphology is a significant factor in prognosis after interventional procedures and that the application of intravascular ultrasound can be useful in determining anatomic configuration, selecting treatment strategy, and defining optimal stenting strategies.
Conclusions: Angiographic classification of LMCA bifurcation lesions is rarely accurate. IVUS shows that the carina is always spared and that the disease is diffuse rather than focal. 61
Relationship Between Baseline Inflammatory Markers, Antiplatelet Therapy, and Adverse Cardiac Events After Percutaneous Coronary Intervention: An Analysis From the Clopidogrel for the Reduction of Events During Observation Trial
Summary: Although various markers of inflammation have been associated with increases in both short-and long-term cardiovascular outcomes, there are very little clinical data providing guidance as to how a patient's inflammatory marker profile can be used to alter therapies and improve that patient's outcome. The current post hoc analysis of the Clopidogrel for the Reduction of Events During Observation trial demonstrated that in patients undergoing a non urgent percutaneous coronary intervention with primarily bare metal stents, baseline levels of high sensitivity C-reactive protein and pregnancy associated plasma protein-A were independently associated with a significantly increased incidence of adverse cardiovascular events at 1 year. Importantly, the clinical benefit of adding long-term clopidogrel to aspirin was greatest in those patients with increased levels of these inflammatory biomarkers. Confirmation of these results in prospective trials may lead to increased opportunities to individualize proven therapies to the patients most likely to benefit from them.
Conclusions:
Patients undergoing non urgent percutaneous coronary intervention who have elevated hs-CRP and PAPP-A have an increased incidence of adverse cardiovascular events. The clinical benefit of adding clopidogrel to aspirin seems greater in those with increased levels of these inflammatory biomarkers. 62
Primary Percutaneous Coronary Angioplasty With and Without Eptifibatide in ST-Segment Elevation Myocardial Infarction: A Safety and Efficacy Study of Integrilin-Facilitated versus Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction (ASSIST)
Summary: The evidence supporting the use of small-molecule glycoprotein IIb/IIIa inhibitors, such as eptifibatide, in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention is limited. To determine whether eptifibatide improves clinical outcomes in patients referred for primary percutaneous coronary intervention, we randomly assigned 400 patients to treatment, initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg). At 30 days, there was no significant difference in the primary end point (death from any cause, recurrent myocardial infarction, or recurrent severe ischemia): 6.5% in the heparin plus eptifibatide group and 5.5% in the heparin-alone group. However, the rates of major or minor bleeding were higher in patients assigned to heparin plus eptifibatide than that in patients assigned to heparin alone (22.4% versus 14.6%). These results will likely be of interest to physicians caring for patients with ST-segment elevation myocardial infarction.
Conclusions:
In patients pretreated with high-dose clopidogrel who were referred for primary PCI, treatment with heparin plus eptifibatide, when compared with heparin alone, did not improve clinical outcomes and was associated with more bleeding complications. 63
Evaluating the Performance of the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines (CRUSADE) Bleeding Score in a Contemporary Spanish Cohort of Patients With Non-ST-Segment Elevation Acute Myocardial Infarction
Summary: The current guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction stress the importance of balancing antithrombotic and interventional therapies with therapeutic risk and urge special attention in groups at high bleeding risk, including women and the elderly. However, determining the net benefit of aggressive treatment in this setting can be complicated because of the lack of quantitative tools able to suggest which treatment strategy might be the most appropriate. The e758 Circulation December 6, 2011
Can Rapid Risk Stratification of Unstable Angina Patients Suppress
Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) score, which involves variables obtained upfront, was found to perform well in the test population. Testing risk scores in a completely independent data set provides a rigorous test of their utility and should be undertaken before its widespread use is recommended. Using data from Ͼ700 patients with non-STelevation acute myocardial infarction admitted to a single Spanish center, we found that this model performs well for most patients except those treated with Ͼ2 antithrombotics who do not undergo cardiac catheterization. The CRUSADE score had excellent capacity in discriminating between high-and low-risk patients (C statistic, 0.82). Moreover, we have established that the CRUSADE risk model maintained its performance even when the study population was stratified by subgroups of age (Ն75 versus Ͻ75 years) (C statistic, 0.80 and 0.81, respectively). The major bleeding predicted by the model closely approximated that observed in this study. Validation of risk models within the population to which they are to be applied is essential. Only then can physicians and healthcare providers be reassured of the performance of the models and subsequently their applicability for risk stratification.
Conclusions:
The CRUSADE risk score was generally validated and found to be useful in a Spanish cohort of patients treated with or without Ն2 antithrombotics and in those treated with or without Ն2 antithrombotics who underwent cardiac catheterization. More studies are needed to clarify the validity of the CRUSADE score in the subgroup treated with Ն2 antithrombotics who do not undergo cardiac catheterization. 64
Incidence and Management of CoreValve Dislocation During Transcatheter Aortic Valve Implantation
Summary: Transcatheter aortic valve replacement is a highly specialized technique offering patients at high risk a new therapeutic option. With more than 20 000 implantations worldwide, it gained reliability as a feasible alternative to open heart surgery. Complications associated with this invasive procedure are different from those after conventional aortic valve replacement and require individual specific management. Between June 2007 and September 2009, 212 patients with severe aortic stenosis had implanted the selfexpandable CoreValve prosthesis (Medtronic Inc, Minneapolis, Minn) through a transfemoral or subclavian access at the German Heart Centre Munich. CoreValve dislocation during transcatheter aortic valve implantation occurred in 10% of the cases. Patients with dislocation of the valve showed a remarkably higher incidence of severe complications, such as coronary ischemia, stroke, and renal failure. Mortality significantly increased when dislocation occurred.
In the present study, we report our experience with intraprocedural valve dislocation with special focus on possible causes and different management strategies of dislocation as well as possibilities of how this complication might be avoided.
Conclusions:
CoreValve dislocation during transcatheter aortic valve implantation occurred in 10% of the cases and significantly increases perioperative risk for severe complications or death. It requires individual specific management and can be managed either interventionally or, rarely, results in open surgery. 65
Impact of Femoral Vascular Closure Devices and Antithrombotic Therapy on Access Site Bleeding in Acute Coronary Syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial
Summary: Vascular closure devices (VCD) have been shown to significantly reduce hemostasis and ambulation times after diagnostic coronary angiography and percutaneous coronary intervention;
however, there is conflicting data on whether VCD increase or decrease the risk of access site bleeding (ASB). To assess the impact of VCD and the antithrombotic regimen on the rates of ASB, we analyzed patients with acute coronary syndrome invasively managed from the large-scale contemporary Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. In this analysis of patients undergoing angiography with or without percutaneous coronary intervention from the femoral approach, there was a significant reduction in the incidence of major ASB and ACUITY non-coronary artery bypass graft major bleeding when a VCD was used. In terms of the individual components of major ASB, both ASB requiring interventional or surgical correction and hematoma Ն5 cm at the puncture site occurred significantly less often in those patients with a VCD. Furthermore, the lowest rate of ASB (Ͻ1%) was observed when patients were treated with bivalirudin monotherapy and a VCD. A stepwise logistic regression revealed significantly reduced risks in the odds of major ASB with bivalirudin monotherapy rather than heparin plus a glycoprotein IIb/IIIa inhibitor and VCD usage (65% and 22%, respectively). Because bleeding is a powerful independent predictor of 30-day mortality in patients with acute coronary syndrome invasively managed, the present findings suggest that the combined use of bivalirudin and a VCD may reduce major ASB in patients with acute coronary syndrome managed with an early invasive strategy from the femoral approach.
Conclusions: In patients with acute coronary syndromes undergoing an early invasive management strategy by the femoral approach, the use of a VCD, bivalirudin monotherapy, or both minimizes rates of major ASB. 66
First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention
Summary: Anticoagulants for percutaneous coronary intervention (PCI) are limited by unpredictable pharmacodynamics and/or lack of active reversibility. The REG1 system is an oligonucleotide RNA aptamer pair comprising the direct rapid-onset factor IXa inhibitor RB006 and its active dose-dependent control agent RB007. REG1 offers effective, predictable, and reversible anticoagulation. We assessed whether anticoagulation through factor IXa inhibition with RB006 could support low-to moderate-risk PCI. This phase IIa study enrolled 26 patients undergoing elective PCI. In a roll-in group, 2 patients received REG1 and glycoprotein IIb/IIIa inhibitors. Then, 24 patients were randomized 5:1 to REG1 (nϭ20) or unfractionated heparin (nϭ4). REG1 patients received RB006 (1 mg/kg) after arterial access. In the first 10 REG1 patients, RB007 was dosed to partially reverse RB006ϫ50% after PCI and to completely reverse RB006 at 4 hours. In the subsequent 10 REG1 patients, RB007 was dosed once to completely reverse RB006 immediately after PCI. All PCI procedures were successful without angiographic procedural thrombotic events or catheter thrombus, and bleeding was infrequent. Baseline plasma and whole-blood activated partial thromboplastin time increased by 2.5-and 1.8-fold 5 minutes after RB006 and remained stable. Activated clotting time was Ն225 seconds in all cases and remained stable with RB006 but trended upward with unfractionated heparin. Partial RB007 reversal reduced RB006 activity by 51Ϯ14% to 68Ϯ15%. Complete reversal reduced RB006 activity by 93Ϯ11% to 103Ϯ13%, depending on the assay. Anticoagulation through factor IXa inhibition with RB006, followed by active reversal with RB007, was feasible and may favorably shift the balance of safety and efficacy during PCI.
Conclusions: This study demonstrates the clinical translation of a novel platform of anticoagulation targeting factor IXa and its active reversal to percutaneous coronary intervention and provides the basis for further investigation. 67
Interventional Therapy of Bifurcation Lesions: A TIMI Flow-Guided Concept to Treat Side Branches in Bifurcation Lesions-A Prospective Randomized Clinical Study (Thueringer Bifurcation Study, THUEBIS Study as Pilot Trial)
Summary: The treatment of coronary bifurcations is a complex problem, and the clinical value of treating side branches remains an unsolved problem in the field of interventional cardiology. We studied the effect of stenting of the main branch with drug-eluting stents ϩ mandatory side branch-PCI (kissing balloons) with provisional side branch stenting versus stenting of the main branch with provisional side branch-percutaneous coronary intervention only when the side branch had a thrombolysis in myocardial infarction flow Ͻ2. As we showed, no significant difference regarding target lesion revascularization or clinical end points was found. The duration of x-ray and the amount of contrast media were significantly less, in favor of the simpler strategy. We conclude that more complex strategies for the treatment of coronary bifurcations may show better short-term angiographic outcome without a clinical benefit for the patients.
Conclusions:
A simple strategy using paclitaxel-eluting stents with only provisional side branch-PCI may be of equal value to a more complex strategy with mandatory side branch-PCI. 68
Does Black Ethnicity Influence the Development of Stent Thrombosis in the Drug-Eluting Stent Era?
Summary: Stent thrombosis is a potentially devastating condition that puts all patients undergoing stent implantation at risk. Variability in the presentation and timing of stent thrombosis can make it an unpredictable and challenging issue to address. Our study demonstrates that black race is an independent predictor of stent thrombosis even when accounting for comorbid confounders and socioeconomic status. These findings suggest that particular populations warrant careful attention with regard to the selection of stent type and antiplatelet therapy. The advent of bedside antiplatelet responsiveness testing may help address this concern. In light of these hypothesis-generating results, further pathogenic studies of genomic and environmental influences should be pursued.
Conclusions: Black race is an independent predictor of definite drug-eluting stent stent thrombosis (ST). Because clopidogrel compliance was higher in black patients and socioeconomic status was not associated with ST, further investigation into the potential mechanisms of this influence of race on ST must be pursued. 69
Prehospital 12-Lead ECG to Triage ST-Elevation Myocardial Infarction and Emergency Department Activation of the Infarct Team Significantly Improves Door-to-Balloon Times: Ambulance Victoria and MonashHEART Acute Myocardial Infarction (MonAMI) 12-Lead ECG Project
Summary: The MonashHEART acute myocardial infarction project adds to the growing body of evidence supporting the use of prehospital triage to improve patient care in the management of ST-elevation myocardial infarction. It supports initiatives aimed at incorporating a multidisciplinary approach to minimize door-toballoon time. Furthermore, these system improvements do not shift the burden of care or significantly consume resources of individual stakeholders who provide the various components of optimal ST elevation myocardial infarction management.
Conclusions:
The performance of prehospital 12-lead ECG triage and emergency department activation of the infarct team significantly improves door-to-balloon time and results in a greater proportion of patients achieving guideline recommendations. 70
Noncardiac Surgery and Bleeding After Percutaneous Coronary Intervention
Summary: The clinical decision on whether to implant a bare-metal or drug-eluting stent during percutaneous coronary intervention is influenced by the perceived likelihood of the patient developing stent thrombosis and is increased in patients having noncardiac surgery or developing bleeding. Using hospital discharge coding, we found that one quarter of patients will undergo noncardiac surgery, and almost one tenth will have significant bleeding during the next 5 years. Half of the bleeding was gastrointestinal and represents the rate in patients taking aspirin alone rather than aspirin and clopidogrel. Increasing age was a strong predictor of both noncardiac surgery and of bleeding. Other predictors of noncardiac surgery and bleeding were a previous history of these events, respectively. Patients with renal failure also had an increased likelihood of both events. Knowledge of these predictors should help clinicians better match the stent to the patient.
Conclusions: Noncardiac surgery is required frequently after PCI, whereas bleeding is less common. Before implanting a drug-eluting or bare-metal stent, individual patient risk stratification by the interventional cardiologist should include assessment of whether there is an increased likelihood of needing noncardiac surgery or developing bleeding. 71
Final 5-Year Results of the TAXUS II Trial: A Randomized Study to Assess the Effectiveness of Slow-and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for De Novo Coronary Artery Lesions
Summary: TAXUS II was the first randomized, double-blind, controlled trial specifically designed to assess the long-term safety and efficacy of the TAXUS paclitaxel-eluting stent for the treatment of de novo coronary artery lesions. It is also the first large TAXUS trial to reach 5-year follow-up and the first trial designed to compare the performance of the slow-release and an investigational moderaterelease formulation of the TAXUS stent with an otherwise identical bare-metal stent. Through 5 years, both the slow-and moderaterelease stents significantly lowered the rates of target-vessel and target-lesion revascularization without increasing the rates of death, myocardial infarction, or stent thrombosis compared with bare-metal stents. The absence of stent thrombosis beyond 2 years in the slowand moderate-release stents with 2 events in the bare-metal stent arm provides reassurance that there is no excessive long-term risk of stent thrombosis with paclitaxel-eluting stents compared with bare-metal stents. Furthermore, the sustained reduction in revascularization rates up to 5 years with both the slow-and moderate-release stents provides evidence that there is no late catch-up phenomenon. Finally, the moderate-release formulation, which delivers a 3-fold greater amount of paclitaxel than the slow-release formulation, demonstrated equivalent safety through 5 years, thereby establishing a clear safety margin for the slow-release formulation, which has been implanted in more than 4 million patients worldwide.
Conclusions: TAXUS II is the first large TAXUS trial to have reached 5-year follow-up. Both the slow release and moderate release stents lowered the rates of target-vessel and target-lesion revascularization, which indicates their sustained efficacy. Furthermore, the low overall rates of all death, myocardial infarction, and stent thrombosis support the long-term safety of the TAXUS stent system. 72 e760 Circulation December 6, 2011
Choice of Reperfusion Strategy at Hospitals With Primary Percutaneous Coronary Intervention: A National Registry of Myocardial Infarction Analysis
Summary: This report uses the National Registry of Myocardial Infarction to better understand patterns of reperfusion therapy use in hospitals with percutaneous coronary intervention capability. The superiority of primary percutaneous coronary intervention versus fibrinolytic therapy in the setting of ST-segment elevation myocardial infarction has been well established, yet its use is not universal at hospitals with this capability in the United States, with more than one third of these facilities also reporting the use of fibrinolytic therapy during recent years. We found that although primary percutaneous coronary intervention use has been increasing steadily over recent years, a substantial number of patients with ST-segment elevation myocardial infarction continue to receive fibrinolytic therapy. This finding is particularly concerning in that primary percutaneous coronary intervention may not be used universally even in high-risk groups of patients who may stand to gain the most from it. We believe these findings have broad implications for the design of future ST-segment elevation myocardial infarction systems of care.
Conclusions: Use of primary PCI, although increasing over recent years, is not universal at PCI-capable hospitals, and optimization of its use at such hospitals represents a potential opportunity to improve outcomes in patients with ST-segment elevation myocardial infarction. 73 
Two-Year Clinical, Angiographic, and Intravascular Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions: The SPIRIT II Trial
Comparison of Plaque Sealing With Paclitaxel-Eluting Stents versus Medical Therapy for the Treatment of Moderate Nonsignificant Saphenous Vein Graft Lesions: The Moderate VEin Graft LEsion Stenting With the Taxus Stent and Intravascular Ultrasound (VELETI) Pilot Trial
Summary: The presence of moderate saphenous vein graft (SVG) lesions is a major predictor of cardiac events late after coronary artery bypass grafting. We designed a pilot study to test the hypothesis of sealing moderate nonsignificant SVG lesions with paclitaxel-eluting stents (PES) to prevent atherosclerosis progression at the level of the moderate SVG lesion while not inducing any deleterious effect on the atherosclerotic process of the nonstented SVG segments. Patients with at least 1 moderate SVG lesion (30% to 60% diameter stenosis) were randomized either to stenting the moderate SVG lesion with a PES (nϭ30, PES group) or to medical treatment alone (nϭ27, medical treatment group). Patients had an angiographic and intravascular ultrasound evaluation of the SVG at baseline and at 12-month follow-up. Mean time from coronary artery bypass grafting was 12Ϯ6 years, and mean low-density lipoprotein cholesterol level was 73Ϯ31 mg/dL. Significant disease progression occurred in the medical treatment group at the level of the moderate SVG lesion as evaluated by angiography and intravascular ultrasound (PϽ0.01 versus baseline; PϽ0.01 versus PES group), leading to a severe flow-limiting lesion or SVG occlusion in up to 22% of the patients compared with none in the PES group (Pϭ0.014). There were no cases of restenosis or stent thrombosis, and no significant atherosclerosis progression occurred at the nonstented SVG segments. At 12-month follow-up, the cumulative incidence of major adverse cardiac events related to the target SVG was 19% in the medical treatment group versus 3% in the PES group (Pϭ0.091). In conclusion, old and moderately diseased SVGs presented a significant and very rapid (within 12 months) disease progression at the sites exhibiting moderate lesions despite optimal control of lowdensity lipoprotein cholesterol levels, and sealing such moderate lesions with PES prevented this process without inducing any deleterious effect on the atherosclerotic disease of nonstented SVG segments. This pilot study provides early evidence that plaque sealing as a new strategy for the treatment of a challenging subset of patients after coronary artery bypass grafting should be explored further.
Conclusions: Stenting moderate nonsignificant lesions in old SVGs with PES was associated with a lower rate of SVG disease progression and a trend toward a lower incidence of major adverse cardiac events at 1-year follow-up compared with medical treatment alone, despite very low low-density lipoprotein cholesterol values. This pilot study supports further investigation into the role of plaque sealing in SVGs. 75
Pharmacodynamic Effects of Concomitant versus Staggered Clopidogrel and Omeprazole Intake: Results of a Prospective Randomized Crossover Study
Summary: A growing body of evidence has shown a broad variability in interindividual pharmacodynamic response profiles to the platelet inhibitor clopidogrel, and patients with reduced platelet inhibition have an increased risk of recurrent atherothrombotic events. Numerous factors may contribute to poor clopidogrel response. Among these, that secondary to a drug interaction with the proton pump inhibitor omeprazole has emerged. The prognostic implications associated with clopidogrel and omeprazole use are not fully elucidated. However, given the high frequency with which both these drugs are prescribed, even a small and limited impairment in clinical outcomes can potentially affect a large number of patients.
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The Food and Drug Administration and the European Medicines Agency have recently recommended avoidance of this drug combination. Nevertheless, because both clopidogrel and omeprazole are rapidly metabolized, many experts have hypothesized and proposed to stagger clopidogrel and omeprazole intake to minimize or even overcome their interaction. However, this strategy has not been validated yet and represents the rationale for the present study design. The findings of the present investigation demonstrate the presence of a pharmacodynamic interaction between clopidogrel and omeprazole when administered concomitantly as well as staggered.
Given the presence of a pharmacodynamic interaction between omeprazole and clopidogrel irrespective of the timing of their administration, use of omeprazole should be avoided in clopidogreltreated patients.
Conclusions: Omeprazole impairs clopidogrel-induced antiplatelet effects in the maintenance phase of treatment irrespective of timing of their administration. 76
Vascular Closure Device Failure: Frequency and Implications: A Propensity-Matched Analysis
Summary: Vascular closure devices (VCDs) are increasingly used after coronary or peripheral vascular procedures, although the data on the efficacy and safety of these devices are controversial. The frequency and consequence of failure of VCDs are not well defined. From a prospective registry of consecutive patients undergoing cardiac catheterization at our center, 9823 patients who received either a collagen plug-based (Angio-Seal) or a suture-based (Perclose) VCD were evaluated. The frequency of VCD failure was 2.7%. Patients with VCD failure had significantly increased risk of any, major, or minor bleeding compared with patients with successful deployment of these devices. In contemporary practice, VCD failure is rare, but when it does fail, it is associated with a significant increase in the risk of vascular complications. Patients with VCD failure should be closely monitored to prevent vascular complications with consequent increase in length of stay. However, it is reassuring that in patients with successful deployment of VCD, the risk of vascular complications is very low.
Conclusions:
In contemporary practice, VCD failure is rare, but when it does fail, it is associated with a significant increase in the risk of vascular complications. Patients with VCD failure should be closely monitored. 77
Frequency of Allergic or Hematologic Adverse Reactions to Ticlopidine Among Patients With Allergic or Hematologic Adverse Reactions to Clopidogrel
Summary: Clopidogrel and ticlopidine are structurally similar. We conducted a retrospective study among patients who had received both drugs and had an allergic or hematologic adverse reaction to one of these drugs to determine the extent and severity of allergic cross-reactivity. Seventy-six patients met the study criteria. Of the 52 patients with an allergic or hematologic adverse reaction to clopidogrel, 14 (27%) were also unable to tolerate ticlopidine. No patient with an allergic reaction to one thienopyridine developed a lifethreatening reaction to the other.
Conclusions:
In patients with an allergic or hematologic adverse reaction to one thienopyridine, there seems to be an increased frequency of such reactions to the other thienopyridine. However, no patient had a life-threatening reaction after exposure to the alternative thienopyridine. 78
Translesional Pressure Gradients to Predict Blood Pressure Response After Renal Artery Stenting in Patients With Renovascular Hypertension
Summary: The clinical usefulness of renal artery stenting in improving blood pressure control in patients with hypertension and a renal artery stenosis has been questioned by recent studies. We evaluated whether translesional pressure gradients using a 0.014-inch pressure guide wire, both at rest and during hyperemia, could help in selecting patients who will benefit from renal artery stenting. Dopamineinduced mean pressure gradient was found to be the strongest predictor of the actual blood pressure improvement at follow-up. Moreover, whereas angiographic parameters of stenosis severity were poor predictors of treatment success, a dopamine-induced mean gradient Ն20 mm Hg reliably predicted a favorable reduction in hypertension after renal stenting. Interestingly, in our study, more than half of the patients selected for renal stenting on the basis of a subjective angiographic evaluation had a hyperemic translesional gradient below the threshold we found to be predictive of hypertension improvement. Thus, a dopamine-induced mean pressure gradient of Ն20 mm Hg is highly predictive of arterial hypertension improvement after renal stenting, and therefore this measurement is useful for appropriate selection of patients with arterial hypertension.
Conclusions:
A dopamine-induced mean pressure gradient of Ն20 mm Hg is highly predictive of arterial hypertension improvement after renal stenting, and therefore this measurement is useful for appropriate selection of patients with arterial hypertension. 79
Catheter-Based Delivery of Fluid Paclitaxel for Prevention of Restenosis in Native Coronary Artery Lesions After Stent Implantation
Summary: Catheter-based local delivery of fluid paclitaxel is a stent-independent, new strategy of intracoronary pharmacotherapy. It offers the advantages of atraumatic homogenous drug delivery to the whole vessel wall, even beyond stent edges, while avoiding the use of polymer as a drug carrier and allowing for rapid reendothelialization. Deeper layers of the injured vascular wall, like dissections, are easily reached by the fluid pharmacological agent. Another fundamental difference to drug-eluting stents or balloons is the concept of delivering paclitaxel independent of the coronary intervention itself by using low, less traumatic pressures. We assessed the safety and efficacy of this new technique in patients with coronary de novo stenoses after implantation of a bare metal stent. The 3-armed LOCAL TAX study compared, for the first time, catheter-based local delivery of fluid paclitaxel to implantation of a drug-eluting stent or a bare metal stent in 204 patients. The results of the LOCAL TAX study showed that local delivery of fluid paclitaxel was safe and significantly reduced neointimal proliferation, restenosis, and clinical events compared with bare metal stent implantation alone. Compared with paclitaxel-eluting stent, catheter-based paclitaxel delivery was not significantly inferior in respect to the primary end point. We believe the concept of delivering drugs in fluid solution with atraumatic catheters to be very promising because it provides major flexibility in 2 crucial aspects: first, the possibility to deliver various compounds or even a combination of different pharmacological principles; and second, the possibility to treat longer or more complex vessel segments medically without mechanical trauma.
Conclusions: Additional antiproliferative treatment of de novo lesions in native coronary arteries with catheter-based delivery of fluid paclitaxel after bare metal stenting was safe and significantly reduced neointimal proliferation, restenosis, and clinical events compared with bare metal stent implantation alone. 80
Choice of Contrast Medium in Patients With Impaired Renal Function Undergoing Percutaneous Coronary Intervention
Summary: Impaired renal function is frequently associated with coronary artery disease, which in turn has a negative impact on the prognosis of patients with chronic renal failure. Revascularization by percutaneous coronary intervention is an effective treatment of coronary artery stenosis. However, it requires the use of iodinated contrast medium that can lead to acute renal failure, in particular in patients with underlying impaired renal function, termed contrastinduced nephropathy. Iodinated contrast media are grouped by their osmolality. Iso-osmolar contrast medium, such as iodixanol, resembles the osmolality of blood, whereas all other commercially available contrast media, such as iomeprol, exhibit higher osmolality. The findings of the contrast study that randomly assigned patients undergoing percutaneous coronary intervention to receive either iodixanol or iomeprol suggest that iso-osmolar contrast medium does not exhibit significantly lower nephrotoxicity compared with higherosmolar contrast medium in unselected patients with chronic renal dysfunction. However, subgroup analysis suggested decreased nephrotoxicity in patients who received high contrast volumes favoring iso-osmolar contrast medium. Considering the results of the Contrast Media and Nephrotoxicity Following Coronary Revascularization by Angioplasty study as well as a recent meta-analysis and other randomized clinical trials that compared iso-osmolar with higherosmolar contrast medium in mixed patient cohorts undergoing coronary angiography, iso-osmolar contrast medium should be considered as a first-line option for use in this high-risk patient population.
Conclusions: Routine use of iso-osmolar contrast medium is not associated with a significant reduction of nephrotoxicity compared with low-osmolar contrast medium in patients with chronic renal failure undergoing PCI. However, a positive effect was seen in the iso-osmolar contrast group for patients receiving high amounts of contrast medium, which awaits confirmation of a specifically designed randomized clinical trial. 81 . PCI use, over time, has expanded to include more patients with severe comorbidities, acute coronary syndromes, and complex, multivessel disease. However, in spite of the sicker patient profile and greater disease burden at baseline, procedural success was achieved more often and with significant reductions in the in-hospital rates of myocardial infarction and emergency coronary artery bypass surgery. Considerable improvements were also observed in the use of secondary evidence-based pharmacological therapy after PCI. Multivariable analyses of outcomes over 1 year show significant, sustained reduction in the need for repeat revascularization but little impact on mortality. PCI, in the last 2 decades, has been increasingly applied to "sicker" patients and yet has achieved substantial improvements in procedural safety and effectiveness (reduced need for repeat procedures). Further studies are warranted to elucidate the impact, or lack thereof, of PCI on long-term mortality.
Twenty-Year Evolution of Percutaneous Coronary Intervention and Its Impact on
Conclusions: Percutaneous interventions, in the last 2 decades, have evolved to include more urgent, comorbid cases, despite achieving high success rates with significantly reduced need for repeat revascularization. 82
Evaluation of a New Heparin Agent in Percutaneous Coronary Intervention: Results of the Phase 2 Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial
Summary: M118 is a novel low-molecular-weight heparin that has been rationally designed to capture the desired attributes of both unfractionated heparin and low-molecular-weight heparin: Potent activity against both factor Xa and IIa, predictable pharmacokinetics after both intravenous and subcutaneous administration, ability to be monitored by use of point-of-care coagulation assays, and reversibility with protamine sulfate. We performed a phase 2 randomized trial to evaluate the safety and feasibility of M118 in the setting of elective percutaneous coronary intervention. The results of the EMINENCE trial demonstrate that M118 is well tolerated and feasible to use as anticoagulant therapy during percutaneous coronary intervention. It exhibits a dose dependent increase in the activated clotting time and is noninferior to unfractionated heparin with respect to a broad composite of end points that reflect complications related to percutaneous coronary intervention. In addition to clinical outcomes, angiographic outcomes were excellent and comparable between unfractionated heparin and M118. Although a range of doses of intravenous M118 were comparable to unfractionated heparin at preventing a broad composite of percutaneous coronary intervention-related complications, we conclude that a dose range of 75 to 100 IU/kg appears most promising and should be tested further in a phase 3 trial.
Conclusions: This phase 2 randomized trial demonstrates that M118 is well tolerated and feasible to use as an anticoagulant in patients undergoing elective percutaneous coronary intervention and forms the basis for further investigation of this agent in ischemic heart disease. 83
Clinical and Angiographic Predictors of Shortand Long-Term Ischemic Events in Acute Coronary Syndromes: Results From the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) Trial
Summary: Whether baseline angiographic characteristics add prognostic insight to clinical factors in the determination of cardiac ischemic events in patients with acute coronary syndromes treated with an early invasive strategy is unclear. Among the 6921 patients included in the angiographic substudy of the ACUITY trial (55.3% percutaneous coronary intervention, 10.9% coronary artery bypass graft, 33.8% medical therapy), composite ischemia occurred in 595 (8.6%) patients at 30 days and in 1153 (17.4%) at 1 year. By multivariable regression analysis methodology, 2 models were constructed, including a model based on clinical parameters only and a clinical and angiographic model for 30-day or 1-year ischemic events. Based on receiver operating characteristic methodology, the c statistic improved for the predictive model that added angiographic to clinical parameters for the 30-day composite ischemia (from 0.62-0.68) and myocardial infarction (from 0.64 -0.71) and 1-year composite ischemia (from 0.61-0.65) and myocardial infarction (from 0.63-0.69) end points. Among acute coronary syndrome patients managed with an early invasive strategy, baseline angiographic markers of disease burden, calcification, lesion severity, lower left ventricular ejection fraction, and morphological characteristics added an important, independent predictive value of 30-day and 1-year ischemic outcomes, beyond the well-recognized clinical risk factors. These findings emphasize the prognostic importance of the diagnostic angiogram in the risk stratification of patients presenting with acute coronary syndromes.
Conclusions: Among ACS patients managed with an early invasive strategy, baseline angiographic markers of disease burden, calcification, lesion severity, lower left ventricular ejection fraction, and morphological characteristics provided important added independent predictive value for 30-day and 1-year ischemic outcomes, beyond the well-recognized clinical risk factors. These findings emphasize the prognostic importance of the diagnostic angiogram in the risk stratification of patients presenting with ACSs. 84
Clinical Feasibility of a Fully Automated 3D Reconstruction of Rotational Coronary X-Ray Angiograms
Summary: The purpose of coronary imaging is to accurately visualize coronary anatomy, detect disease, and guide intervention. Though catheter-based coronary angiography has been a revolutionary tool for patient care, the 2D format of projection images is fundamentally unrealistic and has been shown to lead to misrepresentation of clinically relevant features of the coronary tree and lesions. Technology advancements, while allowing the transition from film to digital images, have not changed the 2D image format during the past 50 years. This article describes the next evolution in this imaging modality: a rotational C-arm acquisition during extended contrast injection that is followed by fully automated reconstruction to provide 3D images of the coronaries. Specifically, this article characterizes for the first time the image quality and potential clinical utility of this new method developed for use in the catheterization laboratory. In this offline study, the volumetric images obtained from a cohort of patients were compared with the acquired 2D images in terms of overall image quality, stenosis detection, potential clinical advantages and disadvantages, and 3D quantitative coronary analysis. After demonstrating the feasibility and reasonable quality of the 3D reconstructions, additional studies are needed to further validate accuracy and to study the added clinical value this technology brings to the care of patients undergoing both diagnostic coronary angiography and subsequent coronary intervention.
Conclusions: Fully automated reconstruction of rotational coronary x-ray angiograms is feasible, produces 3D volumetric images that overcome some of the limitations of standard 2D angiography, and is ready for further implementation and study in the clinical environment. 85
Factors Portending Endoleak Formation After Thoracic Aortic Stent-Graft Repair of Complicated Aortic Dissection
Summary: Endoleaks after stent-graft repair of aortic dissections result in continued perfusion and pulsatility of the false lumen. The pathophysiology of these endoleaks differs from that of endoleaks after repair of aneurysms, reflecting the numerous natural fenestrations and re-entry tears typically present in a dissection outside of the stent-grafted zone. Using an aggressive high-sensitivity imaging protocol, we found evidence of endoleak in 59% of treated patients, but almost half of these resolved spontaneously. Of the remaining leaks, 27% led to delayed false lumen enlargement necessitating reintervention. In patients with dissections complicated by malperfusion, stent-graft repair resulted in a high rate of clinical resolution even in the presence of an endoleak. Thus, the definitions of technical and clinical success need to be amended in this patient population. In contradistinction, persistent perfusion of the false lumen after stent-graft repair in 2 patients with ruptured false lumen aneurysms from chronic dissections proved to be fatal. Occurrence of endoleaks was associated with coverage of the left subclavian artery, small radius of aortic curvature, and poor device apposition to the aortic lesser curve. High rates of endoleak should be expected when treating high-risk dissection patients, and long-term surveillance is particularly crucial in patients with documented endoleaks.
Conclusions: Endoleaks are common after stent-graft repair of aortic dissection and may lead to false lumen enlargement necessitating reintervention. Anatomic complexities such as acute aortic curvature and covered side branches were associated with endoleaks, illustrating the need for dissection-specific device development. 86
Predictors of Long-Term Adverse Outcomes in Patients With Congenital Coronary Artery Fistulae
Summary: Current cardiovascular practice includes closure of all identified audible congenital coronary arterial fistulae. This study describes the long-term follow-up of coronary arterial fistulae at a single referral institution and identifies certain predictors that are associated with adverse outcomes. We raise significant question about this intervention in particular subsets of affected patients due to identification of increased risk of early and late thrombosis and myocardial infarction. We show that coronary fistulae that drain into the coronary sinus are at particularly high risk of adverse outcomes (early and late thrombosis and myocardial infarction) when closure is performed. As well, we found that older patient age and certain modifiable cardiac risk factors, such as tobacco use, diabetes, systemic hypertension, and hyperlipidemia, were associated with similar adverse patient outcomes. Improved registry assessment of such interventions may lead to greater understanding of outcomes in patients with coronary arterial fistulae.
Conclusions: Long-term complications of coronary artery fistulae (CAF) closure may include coronary thrombosis, myocardial infarction, and cardiomyopathy. CAF that drain into the coronary sinus are at particularly high-risk of long-term morbidities after closure, and strategies including long-term anticoagulation should be considered. 87
Role of the Paclitaxel-Eluting Stent and Tirofiban in Patients With ST-Elevation Myocardial Infarction Undergoing Postfibrinolysis Angioplasty: The GRACIA-3 Randomized Clinical Trial
Summary: Fibrinolysis is still administered in a high percentage of patients with acute ST-elevation myocardial infarction in whom primary percutaneous coronary intervention (PCI) cannot be performed in a timely fashion. Routine adjunctive or early postfibrinolytic angiography is often done in these patients to improve outcome. This study was performed to explore the usefulness of administering a IIb/IIIa glycoprotein inhibitor (tirofiban) in patients with acute ST-elevation myocardial infarction treated with postfibrinolytic angioplasty. In this study, tirofiban did not improve any perfusion parameter and was associated with an increase in overall bleeding. Thus, after full-dose tenecteplase, enoxaparin and aspirin are a good antithrombotic combination for a postfibrinolysis PCI reperfusion strategy. In our study, clopidogrel was given after PCI and not on admission, as currently recommended. We further explored the efficacy of the paclitaxel-eluting stent with this regimen. The use of paclitaxel-eluting stents was not associated with an increase in stent thrombosis. Compared with bare-metal stents, paclitaxel-eluting stents significantly reduced late loss but appeared not to reduce in-segment binary restenosis as the rate of binary restenosis with bare-metal stents (11% and not 22%) was unexpectedly low. Implantation of bare-metal stents in postfibrinolysis-PCI patients appeared to be a cost-effective approach compared with paclitaxeleluting stents.
Conclusions: This trial does not provide evidence to support the use of tirofiban after fibrinolysis to improve epicardial and myocardial perfusion. Compared with bare-metal stent, paclitaxel-eluting stent significantly reduced late loss but appeared not to reduce in-segment binary restenosis. 88
Predictive Factors and Impact of No Reflow After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
Summary: No-reflow phenomenon affects 5% to 50% of the patients with acute ST-segment-elevation myocardial infarction undergoing reperfusion therapy. Evidence available suggests that no reflow negates the benefit of reperfusion therapy, promotes subsequent negative remodeling of the left ventricle, and worsens the prognosis of patients with ST-segment-elevation myocardial infarction. This study reported a frequency of no reflow of 9.5% after primary percutaneous coronary intervention (PCI). The lack of residual blood flow in the infarct-related artery, large initial area at risk (quantified with scintigraphy), elevated C-reactive protein level, and previous myocardial infarction were identified as independent correlates of no reflow after primary PCI. There was an intricate relationship between infarct size and no reflow in which larger initial perfusion defects (areas at risk) were associated with more frequent no reflow phenomenon which on its side further increased the infarct size by reducing the salvaging capacity of primary PCI. We found that for every 5% of the left ventricle increase in the initial perfusion defect, the adjusted risk of no reflow was increased by 7%. Patients with no reflow had significantly more reduced left ventricular ejection function 6 months after acute event. By 6 months, coronary angiography showed that normal flow has been restored in 80% of patients with no reflow. No-reflow resolution was associated with better left ventricular ejection fraction compared with patients in whom no reflow persisted by 6 months. No reflow was associated with an Ϸ3-fold increase in the adjusted risk of death within the first year after primary PCI. These findings provide mechanistic information on the harmful effects of no-reflow phenomenon and increase the awareness to better diagnose and treat it in patients with STsegment-elevation myocardial infarction undergoing primary PCI.
Conclusions:
No reflow after primary PCI was associated with reduced myocardial salvage, larger infarct size, worse left ventricular ejection fraction at 6 months, and increased risk of 1-year mortality. In 4 of 5 patients with no reflow after PCI, restoration of normal flow occurred 6 months after reperfusion. 89
Incidence, Predictors, and Prognostic Implications of Hospitalization for Late Bleeding After Percutaneous Coronary Intervention for Patients Older Than 65 Years
Summary: Previous data on bleeding after percutaneous coronary intervention (PCI) have been obtained primarily from randomized trials that focused on in-hospital bleeding. The incidence of late bleeding after PCI, its independent predictors, and its prognostic importance in clinical practice have not been fully addressed. Our findings demonstrate that late bleeding after PCI is associated with substantially increased risk of death and myocardial infarction. The use of triple therapy (ie, aspirin, thienopyridine, and warfarin) is associated with the highest risk of late bleeding in clinical practice.
Conclusions: Hospitalization for late bleeding after PCI is associated with substantially increased risk of death and myocardial infarction.
The use of triple therapy (ie, aspirin, thienopyridine, and warfarin) is associated with the highest risk of late bleeding. 90
Sirolimus-Eluting Stent Treatment at High-Volume Centers Confers Lower Mortality at 6-Month Follow-Up: Results From the Prospective Multicenter German Cypher Registry
Summary: Drug-eluting stents remain a very effective method for the treatment of coronary artery disease. In light of the observed small increased incidence of late thrombosis after implantation of drug-eluting stents, which may manifest by death or large infarctions, certain safety issues should be considered in the complex process of patient selection for patients subjected to this kind of revascularization, implantation techniques, and postprocedural medical therapy. In the present analysis, which included 8201 patients from the multicenter prospective German Cypher Registry who were treated with sirolimus-eluting stents, we found that hospitals with a lower volume of sirolimus-eluting stent-based procedures had significantly higher rates of death and myocardial infarction at 6-month follow-up than high-volume centers. After adjustment for different baseline factors known to be associated with higher mortality and infarction, institutional volume remained an independent risk predictor for death and infarction at 6 months (odds ratio 1.85, 95% confidence interval 1.31-2.59, PϽ0.001 for low-volume centers; odds ratio 1.69, 95% confidence interval 1.29 -2.21, PϽ0.001 for intermediate-volume centers). It was also obvious that patient selection, procedural details, and postprocedural medication differed significantly according to hospital volume, with a stricter implementation of current recommendations in high-volume centers.
Conclusions:
The volume of sirolimus-eluting stent procedures performed on an institutional level was inversely related to death and myocardial infarction but not to target-vessel revascularization at 6-month follow-up. Safety issues are better considered in highvolume centers. These findings have important public health policy implications. 91
Cardioprotective Effects of Ischemic Postconditioning in Patients Treated With Primary Percutaneous Coronary Intervention, Evaluated by Magnetic Resonance
Summary: Acute restoration of myocardial blood flow with primary percutaneous coronary intervention in itself jeopardizes the cardiomyocytes. In some cases, this phenomenon accounts for 50% of the final size of the myocardial infarction. Therefore, it is important to look for means to protect the myocardium during reperfusion. Ischemic postconditioning has been suggested as such a method. Few small studies have demonstrated a beneficial effect of ischemic postconditioning, but the effect on the final infarct size only has been assessed in 38 patients with perfusion defect index measured by scintigraphy as a surrogate measurement for the infarct size. Ischemic postconditioning is simple, cheap, not time consuming, and a safe adjuvant to primary percutaneous coronary intervention, and the method can be introduced in the catheterization laboratories almost overnight. However, the possible introduction of this modality in our view should be demonstrated in a substantial number of patients before taken into consideration. With the use of cardiac magnetic resonance to measure final infarct size in 86 patients, this article demonstrates a decrease in infarct size of 18% with ischemic postconditioning. Being the first to evaluate effect of ischemic postconditioning by cardiac magnetic resonance, we believe that this study makes an important contribution. Furthermore, it is the first, to our knowledge, to suggest an effect on functional status evaluated by New York Heart Association classification.
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Conclusions: Mechanical postconditioning reduces infarct size in patients with ST-segment-elevation myocardial infarction treated with primary percutaneous coronary intervention. The impact of mechanical postconditioning seems to be independent of the size of myocardium at risk. 92
Lack of Correlation Between Noninvasive Stress Tests and Invasive Coronary Vasomotor Dysfunction in Patients With Nonobstructive Coronary Artery Disease
Summary: Coronary vasomotor dysfunction may lead to potential impairment of coronary blood flow during stress and a subsequent imbalance between oxygen demand and supply (myocardial ischemia). Coronary vasomotor dysfunction has been implicated in the pathogenesis and clinical course of atherosclerosis and is associated with a 10-fold increased risk of cardiovascular events. This study suggests that the majority of widely used noninvasive stress tests have limited diagnostic accuracy for identifying coronary vasomotor dysfunction in patients with non obstructive coronary artery disease, with the exercise ECG test being more specific but less sensitive than imaging tests. This may potentially impact the clinical practice of physicians because the presence of a negative noninvasive stress test does not rule out coronary vasomotor dysfunction in symptomatic patients with non obstructive coronary artery disease. This underscores the need for further assessment using invasive cardiac catheterization with vasoactive provocation or novel more sensitive noninvasive imaging for diagnosing coronary vasomotor dysfunction in these patients.
Conclusions:
This study suggests that a negative noninvasive stress test does not rule out coronary vasomotor dysfunction in symptomatic patients with non obstructive coronary artery disease. This underscores the need for invasive assessment or novel more sensitive noninvasive imaging for these patients. 93
Catheter-Based Left Atrial Appendage (LAA) Ligation for the Prevention of Embolic Events Arising From the LAA: Initial Experience in a Canine Model
Summary: Stroke prevention in patients with atrial fibrillation is a significant challenge. Anticoagulation with warfarin is the mainstay of therapy for most of these patients, despite the difficulty of maintaining patients in a correct therapeutic range. Anticoagulation management of these patients is particularly difficult because of bleeding risk, which usually is high in the age group characteristically at risk of atrial fibrillation. Alternative therapies that lessen the necessity of warfarin are highly desirable. Because most thromboembolic events (Ͼ90%) in atrial fibrillation originate from thrombus that develops in the left atrial appendage (LAA), exclusion of the LAA using minimally invasive percutaneous procedures may lessen the risk of stroke. Open heart surgical procedures to exclude the LAA are common; however, recurrence of LAA patency also is common. Implanted devices (Watchman, Amplatz LAA plug) are under clinical investigation. We evaluated a technique of suture closure by using percutaneous pericardial and transseptal access, magnet wires, and an alignment balloon. This approach avoids problems associated with permanent intracardiac device implantation (migration, thrombus formation, and cardiac tamponade). In the future, percutaneous LAA exclusion may prove to be a therapeutic option for patients with atrial fibrillation.
Conclusions: Using a closed-chest approach in the canine model, the catheter-based snare delivery device achieved safe and reliable ligation of the entire LAA. The clinical application of this novel approach may provide an alternative to warfarin or to permanent device implants in patients with nonvalvular atrial fibrillation for the prevention of embolic events originating from the LAA. 94
Long-Term Outcome of Therapeutic Neovascularization Using Peripheral Blood Mononuclear Cells for Limb Ischemia
Summary: Injection of bone marrow mononuclear cells has been reported to promote neovascularization of ischemic tissues effectively. We found that peripheral blood mononuclear cells were as efficient as bone marrow mononuclear cells for the treatment of limb ischemia in animals, and we showed that this treatment was feasible in no-option patients with limb ischemia. However, the long-term outcome of such therapy has not been investigated. In this study, we assessed the long-term outcome of patients receiving this treatment. Improvement of ischemic symptoms was observed in 60% to 70% of the patients. The annual rate of major amputation was decreased markedly by treatment. Improvement of ischemic symptoms was less marked in arteriosclerosis obliterans (ASO) patients on dialysis compared with nonhemodialysis ASO or thromboangiitis obliterans patients. Indeed, the survival rate of these patients was lower than that of nonhemodialysis ASO or thromboangiitis obliterans patients.
Major adverse events such as death, major amputation, and cardiovascular events occurred mostly in ASO patients, and most of them were on dialysis. Thus, we need to be more cautious when we consider this treatment for ASO patients on dialysis. Although it has been suggested that neovascularization might induce the development of atherosclerotic plaque, there was no significant increase of cardiovascular events in responders compared with nonresponders in our study, suggesting that therapeutic neovascularization with peripheral blood mononuclear cells did not promote atherogenesis. Collectively, injection of peripheral blood mononuclear cells seems safe and potentially effective for the treatment of limb ischemia, but the results of a double-blind placebo-controlled study are needed to confirm our findings.
Conclusions: Although this study was not placebo-controlled and these initial results were from a retrospective analysis, injection of peripheral blood mononuclear cells might be safe and potentially effective for the treatment of limb ischemia, but caution is needed when managing ASO patients on dialysis. 95
p27kip1-838C>A Single Nucleotide Polymorphism Is Associated With Restenosis Risk After Coronary Stenting and Modulates p27kip1 Promoter Activity
Summary: The interventional cardiologist needs to decide for every patient undergoing percutaneous coronary intervention whether that individual is optimally treated with a bare metal stent or may need a drug-eluting stent to minimize the risk for in-stent restenosis. Drug-eluting stents, however, require prolonged treatment with antiplatelet drugs and show enhanced in-stent thrombosis. In-stent restenosis is caused mainly by excessive smooth muscle cell proliferation. The cyclin-dependent kinase inhibitor p27kip1 is crucial for the inhibition of the cell cycle and has been reported to be functionally involved in vascular disease. Therefore, we decided to study the association of the p27kip1 gene polymorphism with in-stent restenosis. In 2 independent cohorts of patients who received bare metal stents and were clinically followed up, we identified the association of a single nucleotide polymorphism in the p27kip1 promoter (-838CϾA) with in-stent restenosis. Patients with the -838AA genotype have a decreased risk of target vessel revascularization. This -838A allele corresponds to enhanced p27kip1 promoter activity, which may explain decreased smooth muscle cell proliferation. In conclusion, our data provide novel opportunities for risk stratification of individual patients to support the interventional cardiologist in triaging patients with a low risk of restenosis for treatment with a bare metal stent rather than with a drug-eluting stent.
Conclusions: Patients with the p27kip1-838AA genotype have a decreased risk of in-stent restenosis corresponding with enhanced e766 Circulation December 6, 2011
promoter activity of the -838A allele of this cell-cycle inhibitor, which may explain decreased smooth muscle cell proliferation. 96
Prognostic Value of Isolated Troponin I Elevation After Percutaneous Coronary Intervention
Summary: Although mild elevations of cardiac troponin I (cTnI) I or T are frequent after percutaneous coronary intervention (PCI), their prognostic value is uncertain in patients with normal creatine kinase-MB (CK-MB) after PCI. We studied 2362 patients with normal CK-MB and cTnI values at baseline and no CK-MB elevation after PCI. We found a rise in cTnI after PCI Ͼ1 X upper reference limit (URL) in 932 patients ( Overall, these data suggest that elevated cTnI levels after PCI in the absence of a concomitant rise in CK-MB are associated with only a slightly increased risk of mortality, which is accounted for by the concomitant risk factors. Consequently, the policy for hospital discharge after PCI should not be guided by cardiac cTnI levels when CK-MB is normal but rather by an overall assessment of cardiovascular risk factors.
Conclusions:
In the absence of a rise in CK-MB, elevated cTnI levels after PCI are associated with a modest increased risk of death. However, this is not independent of the concomitant adverse baseline clinical characteristics of these patients. 97
Carotid Duplex Ultrasound Velocity Measurements versus Intravascular Ultrasound in Detecting Carotid In-Stent Restenosis
Summary: Duplex ultrasound criteria for assessing the severity of carotid in-stent restenosis remain poorly defined. We aimed to compare the accuracy of Duplex ultrasound with intravascular ultrasound, which provides a precise assessment of lumen area stenosis and cross-sectional area. Our investigation differs from previous observational studies, in that we were able to analyze "matched" intravascular ultrasound and Duplex images obtained, both at the completion of initial carotid artery stenting and again at follow-up, in all patients. This approach allowed us to develop paired observations for the full spectrum of severity of restenosis and minimize bias toward higher or lower velocities. Our main findings included (i) Duplex ultrasound velocities were good discriminators for detecting significant diameter and lumen area in-stent restenosis;
(ii) optimal duplex ultrasound velocities to detect significant stenosis in stented carotid arteries were greater compared with those for native carotid arteries; and (iii) the combination of duplex velocity criteria increases diagnostic accuracy. Carotid duplex ultrasonography is the ideal noninvasive diagnostic modality to evaluate the long-term patency of carotid stents.
Conclusions: Peak systolic velocity (PSV), end-diastolic velocity, and internal-to-common CA PSV ratio were good discriminators for detecting significant diameter and lumen area greater compared with those for native carotid artery. The combination of duplex velocity criteria increases diagnostic accuracy. 98
Volumetric Intravascular Ultrasound Analysis of Paclitaxel-Eluting and Bare Metal Stents in Acute Myocardial Infarction: The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Intravascular Ultrasound Substudy
Summary: In the prospective, multicenter Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial, patients with ST-segment elevation myocardial infarction within 12 hours of symptom onset were randomized 3:1 to TAXUS EXPRESS paclitaxel-eluting stents or EXPRESS bare metal stents. The intravascular ultrasound substudy enrolled 464 patients with baseline and 13-month follow-up imaging at 36 centers. Paclitaxel-eluting compared with bare metal stents significantly reduced percent net volume obstruction (6.5% [first and third quartiles, 2.2% and 10.8%] versus 15.6% [first and third quartiles, 7.2% and 28.8]; PϽ0.0001) but also resulted in more late-acquired stent malapposition (29.6% versus 7.9%; Pϭ0.0005) resulting from positive vessel remodeling. Plaque and/or thrombus protrusion through stent struts was initially present in 70.4% of paclitaxeleluting stents and 64.8% of bare metal stents; all resolved during follow-up. New aneurysm formation, stent fracture, and subclinical thrombus were uncommon, although seen only in paclitaxel-eluting stents. The present data demonstrate a reduction in neointimal hyperplasia and restenosis in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents compared with bare metal stents. Long-term follow-up is required to establish whether the increased frequency of late-acquired stent malapposition with paclitaxel-eluting stents has clinical significance.
Conclusions: Paclitaxel-eluting stents compared with bare metal stents significantly reduce neointimal hyperplasia in patients with ST-segment elevation myocardial infarction but also result in a high frequency of late-acquired stent malapposition as a result of positive vessel remodeling. Ongoing long-term follow-up is required to establish the clinical significance of these findings. 99
Long-Term Follow-Up on a Large Cohort of "Full-Metal Jacket" Percutaneous Coronary Intervention Procedures
Summary: As interventional cardiologists tackle more complex lesions during percutaneous coronary interventions, practice frequently moves ahead of published data. The procedural "full-metal jacket" is one such example: defined as Ն60 mm of continuous overlapping drug-eluting stent to a single vessel. In this journal, we report long-term outcomes on the largest registry of full-metal jacket lesions published to date. We report encouraging safety outcomes, with low-stent thrombosis, myocardial infarction, and cardiac death rates of 2.6%, 3.5%, and 3.6%, respectively, at a median follow-up duration of 39 months. Target lesion revascularization rates are high at 23.4%, but the majority of these procedures are for focal restenosis only, and only 4.6% of the cohort required a subsequent second target lesion revascularization, despite having a major reconstruction of an epicardial vessel at the index procedure. These data suggest that appropriately selected, very long lesions can be treated relatively safely and should the clinical scenario demand it, we should not be afraid of treating very long lesions with drug-eluting stents.
Conclusion: When very long lesions (Ն60 mm) were treated using overlapping drug-eluting stents, 23.4% required a further procedure for restenosis at 3-year follow-up. However, myocardial infarction, stent thrombosis, and cardiac mortality rates were relatively low. 100 investigated whether calculating a tailored dose of contrast based on the size of the patient (body weight, kilograms) and baseline renal function (serum creatinine, milligrams per deciliter) could place patients at higher or lower risk of CI-AKI during a percutaneous coronary intervention. This tailored contrast dose is referred to as the maximum allowable contrast dose (MACD): 5 mLxbody weight (kg)/serum creatinine (mg/dL). We discovered that when the MACD dose was exceeded during a percutaneous coronary intervention, the risk of CI-AKI increased linearly, supporting a dose-dependent effect. This work can assist operators in approximating the increased risk of CI-AKI when the MACD is exceeded by 0% to 50% (60% increased risk of CI-AKI), 50% to 100% (2-fold increased risk of CI-AKI), and Ͼ100% (3-fold increased risk of CI-AKI). The MACD may be used as a tool to guide safe dosing of contrast in the catheterization laboratory and incorporated as part of the team's "timeout" before initiating a case.
Conclusions: Contrast volume is a key risk factor for CI-AKI and matters the most in the highest-risk patient. The incremental use of contrast beyond the MACD is associated with an increased risk of CI-AKI. 101
Long-Term Results of Carotid Artery Stents to Manage Symptomatic Carotid Artery Stenosis and Factors That Affect Outcome
Summary: This article reviews routine carotid stenting practice in a cohort of purely symptomatic patients focusing on patient and procedural factors that influence long-term outcome. This sort of analysis has never previously been published to our knowledge and compliments the new data available from the recently published carotid stenting studies. It has highlighted the possible importance of residual stenosis at the time of stenting or restenosis of Ͼ50% as a possible risk factor for future stroke recurrence. This important finding needs further validation in another cohort of patients. We have also shown that some factors previously felt to affect long-term outcomes in univariate analysis have a more limited impact than previously thought. Clinicians and patients should also be aware that stenting in patients with cerebral events seems to have up to 6 times the risk of retinal events. It has not been possible with our cohort to determine the individual benefits of each of the procedural changes in the carotid stenting process, but we have shown that the modern therapies applied during stenting have significant benefits.
Conclusions:
Patients with retinal presentations are a lower risk group to treat. Residual stenosis or restenosis Ͼ50% has a statistically significant trend to an increased risk of recurrence for ipsilateral stroke in the long term in this population. In our patients, a combination of procedural modifications and pharmacological changes seems to improve outcomes. 102
Ultra-High-Pressure Balloon Angioplasty for Treatment of Resistant Stenoses Within or Adjacent to Previously Implanted Pulmonary Arterial Stents
Summary: In a series of 29 patients with congenital heart disease and a total of 34 pulmonary arterial stenoses within or adjacent to previously placed stents that were resistant to previous attempts at high-pressure dilation, ultrahigh-pressure balloon angioplasty was effective at relieving the obstruction 91% of the time. Although this is a small series, our results support the use of ultrahigh-pressure balloons in this application. The ability of ultrahigh-pressure balloons to fracture completely expanded and shortened stents may overcome one of the major limitations to the use of stents in small children and effectively extend the utility of stents in the pediatric population. Given the high inflation pressures and noncompliant behavior of ultrahigh-pressure balloons, we believe that it is important to use conservative balloon:waist ratios to minimize potential trauma at and adjacent to the lesion being treated.
Conclusions: Ultra-high-pressure angioplasty was safe and effective for treatment of stent-related resistant pulmonary arterial stenosis in this series; the ability to fracture maximally expanded stents may extend the utility of stents in the pediatric population. 103
Effect of Length and Diameter of Drug-Eluting Stents versus Bare-Metal Stents on Late Outcomes
Summary: Knowledge of the relative benefits and risks of drug eluting stent (DES) compared to bare metal stents (BMS) is important for the appropriate performance of percutaneous coronary intervention. We found that in the use of long stents (Ͼ23 mm) the BMS was associated with higher rates of repeat revascularization and the composite of nonfatal MI or death compared with the DES. We also evaluated the influence of the diameter of the treated coronary artery. Recent studies suggest that there may be minimal benefit of the DES in larger-diameter coronary arteries (ie, Ն3.5 mm) as compared to BMS. Our observations support these observations for stent lengths Ͻ23 mm but not Ͼ23 mm. We suggest that as stent length increases, greater preference should be given to the use of DES rather than BMS.
Conclusions: Independent of adverse patient and lesion characteristics, DES demonstrated significantly lower hazard of target-vessel revascularization and nonfatal MI or death at 2 years compared with BMS within the longest stented lengths (Ͼ23 mm) and largest diameters (Ͼ3.4 mm). 104
Anatomic and Functional Evaluation of Bifurcation Lesions Undergoing Percutaneous Coronary Intervention
Summary: To develop improved strategies and devices for coronary bifurcation lesions, better insight into both the anatomic and functional aspects of bifurcation lesions is required. We sought to investigate the mechanism of geometric changes after MB stent implantation and to identify the predictors of functionally significant jailed SB lesions with both IVUS and FFR. IVUS analyses showed that SB jailing can occur both by carina shift and plaque shift. Angiographic determinants of a functionally significant SB lesion were the preintervention SB percent diameter stenosis and the MB minimum lumen diameter located distal to the SB ostium, reflecting the degree of underlying disease and carina shift, respectively. However, it was difficult to predict the functional significance of each jailed SB lesion. This study showed the complex mechanism of SB jailing and its individual variability, which explains the difficulty of angiographic assessment in evaluating the functional significance of a jailed SB.
Conclusions: Both plaque shift from the MB and carina shift contribute to the creation/aggravation of an SB ostial lesion after MB stent implantation. Anatomic evaluation does not reliably predict the functional significance of a jailed SB stenosis. 105
Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional Recovery and Remodeling After Primary Angioplasty
Summary: Mounting interest has emerged regarding the role of mechanical devices for thrombus removal for improving reperfusion and survival after primary percutaneous coronary intervention. Whether observed improvements in myocardial reperfusion and clinical outcome with thrombus aspiration are directly connected to better follow-up left ventricular function and geometry has not yet been clarified. In this study, we evaluated the effect of manual thrombus aspiration on tissue-level perfusion, as assessed using ST-segment resolution, Thrombolysis in Myocardial Infarction myo-cardial perfusion grade, and myocardial contrast enhancement by intracoronary myocardial contrast echocardiography and on the time course of changes in regional and global LV function and volumes in patients with ST-segment elevation myocardial infarction. Our study demonstrates that manual thrombus aspiration in the setting of primary percutaneous coronary intervention improves myocardial tissue-level perfusion and that this improvement is paralleled by a significant improvement in regional and global left ventricular function and a significant reduction of left ventricular remodeling at 6 months. These results may provide the pathophysiological missing link between thrombus removal, tissue-level perfusion, left ventricular remodeling, and clinical outcome and support the use of manual thrombus aspiration as routine adjunct therapy in the setting of primary percutaneous interventions.
Conclusions: Manual thrombus aspiration in the setting of primary percutaneous coronary intervention improves myocardial tissuelevel perfusion as well as left ventricular functional recovery and remodeling. 106
Development of a Novel Prohealing Stent Designed to Deliver Sirolimus From a Biodegradable Abluminal Matrix
Summary: Very late stent thrombosis is a devastating and potentially lethal complication occurring almost exclusively among patients treated with drug-eluting stents. Although the mechanisms responsible for this phenomenon are still unclear, it is believed that delayed vascular healing plays a major role in the development of very late stent thrombosis. Thus, there is substantial clinical potential for stent platforms that integrate the antiproliferative effect of sirolimus elution with the vascular healing/reendothelialization effect of endothelial progenitor cell (EPC) capture (anti-CD34). Functional reendothelialization through EPC capture could increase natural healing while reducing the thrombotic potential as well as the need for prolonged antiplatelet therapy. A paradox in the development of drug-eluting stent technology is that the beneficial effect of drug elution is overshadowed by the inhibition of stent endothelialization. Combining drug elution with EPC capture could potentially achieve an optimum hybrid technology harnessing the antiproliferative qualities of drug elution with the prohealing aspects of EPC capture. We found that by separating EPC capture from sirolimus delivery through application of the elution polymer to the abluminal surface of the stent, we could potentially improve the functionality of these hybrid stents.
Conclusions: Both optical coherence tomography and histology demonstrate that anti-CD34 sirolimus-eluting stents promote endothelialization while reducing neointimal formation and inflammation. 107
Iodixanol versus Low-Osmolar Contrast Media for Prevention of Contrast Induced Nephropathy: Meta-analysis of Randomized, Controlled Trials
Summary: Because contrast-induced nephropathy is associated with significant morbidity and mortality, we performed a metaanalysis of 36 trials to assess the efficacy of iodixanol compared with lowosmolar contrast media. In this study, iodixanol showed no statistically significant reduction in contrast-induced nephropathy incidence below that observed with heterogeneous comparator agents. We were unable to show a significant benefit in any high-risk subgroups; there was a significant benefit of iodixanol when compared with iohexol alone. The heterogeneity of the studies included reflects the variation seen in general clinical practice and suggests that a general benefit of iodixanol relative to low-osmolar contrast media has not been established. Although the results could be applied to patients undergoing any contrast requiring radiographic procedure, we believe that the study is most applicable to patients undergoing cardiac angiography because the majority of studies included in our analysis were performed in cardiac patients.
Conclusions: Analysis of aggregated summary data from multiple randomized, controlled trials of iodixanol against diverse lowosmolar contrast medias for heterogeneous procedures and definitions of contrast induced nephropathy show an iodixanol-associated reduction that is suggestive but statistically nonsignificant. 108
Long-Term Paclitaxel-Eluting Stent Outcomes in Elderly Patients
Summary: The elderly constitute an expanding population segment, and because of an age-related predisposition to coronary disease, the number of elderly patients undergoing revascularization is increasing. Although drug-eluting stents have become a mainstay of percutaneous coronary intervention overall, the risk/benefit of drugeluting stents use in the elderly, who may be at higher risk because of comorbid conditions, remains poorly defined. This gap in knowledge can result in some physicians avoiding drug-eluting stents in elderly patients, potentially depriving them of a beneficial treatment option. In this study, we retrospectively assessed Ͼ10,000 patients drawn from randomized trials and monitored registries of the TAXUS paclitaxel-eluting stent to assess how multiyear clinical outcomes varied with patient age. Compared with younger cohorts, TAXUS-treated trial patients aged Ͼ70 years had higher annualized death rates, but similar rates of myocardial infarction, stent thrombosis, and target lesion revascularization, through 5 years. These rates of death, myocardial infarction, and stent thrombosis for TAXUS were also similar to patients randomized to bare-metal stents, although target lesion revascularization was significantly reduced by TAXUS. The "real-world" registry patients echoed these trends through 2-year follow-up; patients aged Ͼ70 years had lower myocardial infarction, stent thrombosis, and target lesion revascularization rates than younger patients, but significantly higher annualized death rates comparable with those of age and gender-matched norms in the general population. This study extends our knowledge about drug-eluting stent outcomes in this growing population and demonstrates that TAXUS is a safe and an effective treatment option in elderly patients who have indications for revascularization and suitable coronary anatomy.
Conclusions: This analysis of almost 10 000 patients demonstrated that percutaneous coronary intervention with paclitaxel-eluting stents is a safe and an effective treatment option that should not be withheld based on age. 109 Bayesian methods, unlike standard methods, are able to provide inferences of direct clinical utility such as the probability that one intervention is better than another. We found no difference in mortality, myocardial infarction, or stent thrombosis with DES use compared with BMS. However, DES implantation significantly reduced major adverse cardiac events (death, myocardial infarction, and TVR), driven essentially by lower TVR rates. TLR was also significantly less frequent with DES implantation. This analysis suggests that DES implantation in SVG disease appears effective in reducing the need for repeat revascularization of SVG atherosclerotic lesions. DES are not associated with an important harm signal but further data are needed.
Six-Month Results of the NEVO RES-ELUTION I (NEVO RES-I) Trial: A Randomized, Multicenter Comparison of the NEVO Sirolimus-Eluting Coronary Stent With the TAXUS Liberté Paclitaxel-Eluting Stent in De Novo Native Coronary Artery Lesions
Conclusions:
In this study-level meta-analysis, the largest ever reported and the first using bayesian methods, the use of DES for the treatment of SVG disease reduces target vessel revascularization and target lesion revascularization procedures compared with BMS. Although there is no evidence to date to suggest increased rates of mortality, myocardial infarction, or stent thrombosis, further data are needed to address this safety issue. 111
Immunohistochemical Characterization of Neotissues and Tissue Reactions to Septal Defect-Occlusion Devices
Summary: More than 100,000 septal defect-occlusion devices have been implanted as yet. Much experience has been gained with the implantation procedure during the past years, making it a safe and effective procedure nowadays. In contrast, little is known on the healing response after implantation. To our knowledge, this study is the first systematical evaluation of tissue reactions using immunostainings in a series of 10 septal defect-occlusion devices, which were explanted from humans for malpositioning, residual shunting, or other reasons. Superficial cells could be identified as endothelial cells. The time course of neoendothelialization, as seen in our study, further supports the clinical practice of anticoagulant or antiplatelet therapy for 6 months after implantation. This time interval should be sufficient to prevent thromboembolic events due to thrombus formation at the foreign material surface of cardiovascular implants. As seen by immunohistochemical staining, the process of complete cellular organization of the initially formed fibrin deposits takes longer than previously reported. Even in a device which had been implanted for 15 months, residual islets of condensed fibrin were seen. The cellular components of the neotissue were demonstrated to mainly consist of fibroblast-like cells, which showed a slowly progressing maturation pattern over time.
Conclusions: This is the first presentation of results from serial immunohistochemical staining of a collection of explanted human septal-occlusion devices. A time-dependent maturation pattern of the fibroblast-like cells in the neotissues around the implants could be described. Neoendothelialization was seen in all specimens with implantation times of 10 weeks or more. The time course of neoendothelialization, as seen in our study, further supports the clinical practice of anticoagulant or antiplatelet therapy for 6 months after implantation. This time interval should be sufficient to prevent thromboembolic events due to thrombus formation at the foreign surface of cardiovascular implants. 112
Safety and Efficacy of the Subclavian Approach for Transcatheter Aortic Valve Implantation With the CoreValve Revalving System
Summary: Whether the subclavian artery can be used as the vascular approach for transcatheter aortic valve implantation (TAVI) is a particularly significant question because a number of patients screened for TAVI have contraindications for femoral access. Our report describes the procedural results of TAVI with the CoreValve Revalving System placed through the subclavian artery in 54 consecutive patients. Procedural success was obtained in 100% of the subclavian access patients, with no intraprocedural deaths. The most common in-hospital complications were a new left bundlebranch block (27.8%) and the need for pacemaker (18.5%). No specific complications related to subclavian access (vessel rupture, vertebral or internal mammary ischemia) were observed. Six-month mortality was 9.4%, whereas the rate of valve-related adverse events was 13.6%. When comparing the outcomes of these patients with those treated by the femoral artery approach, no significant differences were observed. Our preliminary data show that the subclavian approach is safe and feasible, with excellent procedural success and low in-hospital complication rates, similar to those of the femoral approach. Interestingly, the subclavian approach did not require a learning curve. Vascular access through the subclavian artery may expand the proportion of patients with aortic stenosis for treatment by TAVI.
Conclusions: TAVI through the subclavian approach appeared feasible and safe, with excellent procedural success and low in-hospital complication rates. This new technique allows patients with contraindications to the femoral approach to be treated with TAVI. 113
Polymer-Free Biolimus A9-Coated Stent Demonstrates More Sustained Intimal Inhibition, Improved Healing, and Reduced Inflammation Compared With a Polymer-Coated Sirolimus-Eluting Cypher Stent in a Porcine Model
Summary: Drug-eluting stents still have late stage disadvantages that might be attributable to the polymer. We hypothesized that polymerfree drug release may reduce late events and developed a newly designed polymer-free Biolimus A9 -coated stent. The BioFreedom stent has 3 unique features. First, BioFreedom stents release the antiproliferative agent directly from a mechanically modified textured surface of the stent without the use of polymer. Second, Biolimus A9 is a highly lipophilic drug, which means it easily crosses the cell membrane to achieve therapeutic effects in its target tissue. Third, BioFreedom stents use asymmetrical coating on the outside surface of the stent. To test the hypotheses, we compared BioFreedom stents to a polymer-coated sirolimus-eluting Cypher stent and a bare-metal stent in an overstretch coronary mini-swine model. As a result, BioFreedom stents demonstrated equivalent early reduction of intimal proliferation with late efficacy compared with sirolimus-eluting Cypher stents. There appeared to be delayed healing and persistent inflammation in sirolimus-eluting Cypher stents compared with BioFreedom stents. The use of this new generation of polymer-free drug-eluting stents versus traditional polymeric drug-eluting stents may be beneficial and should be examined in a randomized clinical trial.
Conclusions:
The polymer-free Biolimus A9 -coated stent demonstrates equivalent early and superior late reduction of intimal proliferation compared with sirolimus-eluting Cypher stent (SES) in a porcine model. After implantation of BioFreedom stent, delayed arterial healing was minimal, and there was no increased inflammation at 180 days compared with SES implantation. The use of polymer-free stents may have a potential long-term benefit over traditional polymeric-coated drug-eluting stents. 114
Long-Term Prognosis in an ST-Segment Elevation Myocardial Infarction Population Treated With Routine Primary Percutaneous Coronary Intervention: From Clinical Trial to Real-Life Experience
Summary: Primary percutaneous coronary intervention (pPCI) is the recommended treatment for ST-segment elevation myocardial infarction. The short-term benefit of pPCI compared with fibrinolyses has been demonstrated in a number of trials, the largest of which was the Danish multicenter randomized study on thrombolytic therapy versus acute coronary angioplasty in acute myocardial infarction (DANAMI)-2 trial. However, our knowledge of long-term prognosis-especially in real-life ST-segment elevation myocardial infarction-populations-is very limited. Furthermore, it is questionable whether patients treated during off hours experience similar outcomes compared with patients treated during office hours. This article demonstrates that ST-segment elevation myocardial infarction patients treated with pPCI have similar baseline variables and exhibited similar good long-term prognosis similar to that in STsegment elevation myocardial infarction patients in the landmark DANAMI-2 trial. Furthermore, our results suggest that patients treated with routine pPCI during off hours do not experience poorer long-term outcomes compared with patients treated during office hours. This indicates that routine pPCI-performed within an effective organizational structure-can be applied successfully in a real-life population around the clock, even when most patients are transported to the angioplasty center from noninvasive centers.
Conclusions: This study shows that ST-segment elevation myocardial infarction patients treated with contemporary routine pPCI achieve a similar long-term prognosis as patients in the landmark randomized pPCI trial (DANAMI-2). Furthermore, the long-term prognosis was the same regardless of whether the pPCI was performed during off hours or office hours. Thus, pPCI including transportation of patients from noninvasive centers can be applied successfully in a real-life population. 115
Drug-Eluting Stents in Bifurcations: Bench Study of Strut Deformation and Coating Lesions
Summary: The side-branch ostium is the most common site for restenosis after drug-eluting stent (DES) deployment in coronary bifurcation lesions. The aim of our study was to analyze the consequences of the kissing postdilatation technique on 5 DESs, using microfocus x-ray computed tomography and scanning electron microscopy. This bench test analysis suggests that when commercially available DESs are subjected to simultaneous kissing balloon postdilatation in an unconstrained model, elliptical deformation of the proximal segment, reduction of stent-to-artery ratio, and polymer coating damage at the side branch ostium are observed. These DES changes may impair local drug delivery, thus limiting the effectiveness of these DESs and contributing to ostial side branch restenosis.
The results of our study could clarify restenosis mechanisms at the origin of the side branch in the case of kissing deployment of DESs and could lead to improving DESs or their use in clinical practice.
Conclusions: Commercially available DESs subjected to simultaneous kissing balloon postdilatation in an unconstrained model may contribute to side branch ostial restenosis by proximal segment elliptic deformation and damage to the polymer coating. 116
Diabetes Duration Is Associated With Increased Thin-Cap Fibroatheroma Detected by Intravascular Ultrasound With Virtual Histology
Summary: Patients with diabetes are at especially high risk for early cardiovascular death and nonfatal myocardial infarction. Duration of diabetes is thought to be an important determinant of cardiovascular risk for diabetic patients. In this study, we set out to determine whether duration of diabetes was associated with the frequency of a vulnerable plaque phenotype termed "thin-cap fibroatheroma," as identified by intravascular ultrasound with virtual histology. Thincap fibroatheroma is believed to be highly prone to risk of plaque rupture. We performed intravascular ultrasound with virtual histology in 54 patients with diabetes who were classified by duration of diabetes, either less than or greater than 10 years. Patients with diabetes Ͼ10 years had more plaque overall as well as plaque classified as thin-cap fibroatheroma by intravascular ultrasound with virtual histology than patients who had diabetes Ͻ10 years. This relationship persisted when patient characteristics, risk factors, and drug therapy for diabetes were taken into account. This intravascular ultrasound study suggests that there is an association between diabetes duration and the frequency of vulnerable plaque.
Conclusions: In this cohort, longer duration of diabetes was associated with intravascular ultrasound-defined thin-cap fibroatheroma a plaque phenotype associated with risk of rupture and coronary heart disease events. 117
Coronary Spasm Preferentially Occurs at Branch Points: An Angiographic Comparison With Atherosclerotic Plaque
Summary: Coronary spasm plays an important role in the pathogenesis of ischemic heart disease. However, similarities and differences between coronary spasm and atherosclerosis are not known. This study examined the angiographic characteristics of coronary spasm in comparison with those of atherosclerotic plaque, first in the angiographically normal or almost normal coronary arteries and then in those with atherosclerotic plaque. The results showed that diffuse spasm involving the entire artery appeared in the substantial number of the angiographically normal arteries and that spasm preferentially occurred at branch points in both the angiographically normal arteries and those with plaque. On the other hand, plaque was predominantly localized at nonbranch point sites of the curved proximal segments. Most spasms did not occur at the sites of plaque. These results suggest that coronary spasm may be a manifestation of a distinct type of arteriosclerosis different from the lipid-laden coronary atherosclerosis. This study, thus, may provide a new insight into the pathogenesis not only of coronary spasm but also of atherosclerosis and may explain at least partially the decline of the number of coronary spasm with the increase of hyperlipidemia among Japanese in recent years.
Conclusions: Coronary spasm preferentially occurred at branch points and nonplaque sites, whereas the atherosclerotic lesion was predominantly localized at the nonbranch points of the curved proximal segments. Coronary spasm may thus be a manifestation of a distinct type of arteriosclerosis different from the lipid-laden coronary atherosclerosis. 118
The Adverse Long-Term Impact of Renal Impairment in Patients Undergoing Percutaneous Coronary Intervention in the Drug-Eluting Stent Era
Summary: In patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention, procedural success is reduced and in-hospital and 1-year outcomes are poor. Little is known about outcomes in this cohort beyond 1 year, and the effect of CKD on late outcomes in contemporary practice with drug-eluting stents remain unknown. In a large prospective registry, we found the presence of moderate to severe CKD (creatinine clearance Ͻ60/mL/ min), present in a quarter of all patients undergoing percutaneous coronary intervention, to be associated with significantly lower survival and major adverse cardiac events-free survival out to 7 years. Only cardiogenic shock and severe left ventricular dysfunction were more predictive of worse long-term outcomes. In contrast to patients with more normal renal function, in those with CKD, drug-eluting stents use was not associated with a lower late mortality. An association with a lower rate of major adverse cardiac events was primarily a function of a decreased need for repeat revascularization. Poor late outcome after percutaneous coronary intervention in patients with CKD likely occurs as a result of a constellation of unfavorable anatomic, inflammatory, biochemical, and rheological factors, Although the use of drug-eluting stents may in part mitigate poorer late outcomes, patients with CKD remain at high risk. Clinicians must use all strategies possible to optimize percutaneous coronary intervention results and to ensure optimal use of proven therapies in this increasingly important high-risk patient cohort.
Conclusions: In a large registry of "all comers" for percutaneous coronary intervention, CKD was an independent predictor of adverse late outcomes. DES use may be associated with improved long-term outcomes in this high-risk cohort, but further prospective studies are required. 119
Impact of NAD(P)H Oxidase-Derived Reactive Oxygen Species on Coronary Arterial Remodeling: A Comparative Intravascular Ultrasound and Histochemical Analysis of Atherosclerotic Lesions
Summary: Arterial remodeling has been considered a biological phenomenon to maintain constant flow despite increases in atherosclerotic mass. Recent accumulating evidence, however, indicates that coronary arterial remodeling does not necessarily have favorable effects on the cardiovascular system, because it is associated with plaque vulnerability. Arterial remodeling is a complex process in which reactive oxygen species (ROS) are induced, but the precise mechanisms remain to be elucidated. Oxidative stress induced by ROS exerts profound effects on the function of vascular cells, including cellular proliferation, phenotypic changes in vascular smooth muscle cells, and deposition of the extracellular matrix. To clarify the roles of ROS derived from NAD(P)H oxidase in the process of arterial remodeling in patients with coronary artery disease, we evaluated the relation of preinterventional intravascular ultrasound findings of atherosclerotic plaque with ROS generation and NAD(P)H oxidase p22phox expression in corresponding specimens obtained by directional coronary atherectomy. ROS generation and p22phox expression in lesions with expansive remodeling were significantly higher than in lesions without remodeling. Both ROS generation and p22phox expression were significantly correlated with the intravascular ultrasound-derived remodeling index. Coronary expansive remodeling was associated with inflammatory responses. Our observation indicates that NAD(P)H oxidase-derived ROS have a significant role in the coronary arterial remodeling process associated with plaque vulnerability in patients with coronary artery disease. Recent prospective population studies demonstrate that nonspecific antioxidant vitamins likely have no beneficial effect on cardiovascular disease; however, our investigation suggests that NAD(P)H oxidase might be an effective therapeutic target molecule for coronary artery disease
Conclusions: Simultaneous examination with intravascular ultrasound and immunohistochemistry analyses suggests that NAD(P)H oxidase-derived ROS is related to the coronary arterial remodeling process associated with plaque vulnerability. 120
Rapamycin-Eluting Stents in the Arterial Duct: Experimental Observations in the Pig Model
Summary: Maintaining arterial duct patency by stent implantation may be advantageous in congenital heart disease management algorithms. Rapamycin has antiproliferative properties and inhibits smooth muscle cell migration. In this study, bare metal and rapamycin-eluting stents were implanted into the arterial duct of 28 newborn pigs. At 2 weeks after stent implantation, minimal neointimal proliferation was observed in both the bare metal and rapamycin-eluting groups. At 4 weeks, luminal diameters were significantly increased in the rapamycin-eluting stent group. The difference at 6 weeks was not statistically significant. In vitro studies examining the cultures of duct-derived smooth muscle cells in the absence or presence of rapamycin demonstrated 50%-lower proliferation rates in the rapamycin group. This study demonstrates that rapamycin has antiproliferative actions on the arterial duct. Drugeluting stents may be a more efficient tool than current palliative options for maintaining patency in critically duct-dependent states, but there may be a finite time-related benefit.
Conclusions: Rapamycin has antiproliferative actions on the arterial duct. Drug-eluting stents may be a more efficient tool than current palliative options for maintaining patency in critically ductdependent states, but there may be a finite time-related benefit. 121 
